

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE EMERGE PLATFORM OF THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE") IN COMPLIANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED (THE "SEBI ICDR REGULATIONS")



[Please scan this QR Code
to view the Addendum]



ABH HEALTHCARE LIMITED
Corporate Identity Number: U85300PB2021PLC052886

Our Company was originally incorporated as a private limited company in the name and style of "ABH Healthcare Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated March 2, 2021 issued by Registrar of Companies, Central Registration Centre. Further, in accordance with the main objects, our Company acquired the sole proprietorship concern of Dr. Kamal Baghi, our Promoter in the name "Anil Baghi Hospital" pursuant to a Business Transfer Agreement dated March 16, 2022. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the Extraordinary general meeting of our members held on October 7, 2024 and consequently, the name of our Company was changed to "ABH Healthcare Limited", and a fresh certificate of incorporation consequent upon conversion dated November 15, 2024 was issued by the Registrar of Companies, Chandigarh.

For further details, see "**History and Certain Corporate Matters**" on page 158 of the Draft Red Herring Prospectus.

Registered Office: Anil Baghi Road, Ferozepur, Punjab - 152002, India

Tel No. / Mob No.: +91 7888690018; **Email:** investor@anilbaghihospital.com ; **Website:** www.abhhealthcare.org

Contact Person: Rahul Sharma, Company Secretary & Compliance Officer

NOTICE TO INVESTORS: SECOND ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED JUNE 27, 2025 (THE "ADDENDUM")

OUR PROMOTERS: DR. KAMAL BAGHI, DR. SAURABH BAGHI AND DR. VAISHALI SAINI

INITIAL PUBLIC ISSUE* OF UPTO 34,29,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF ABH HEALTHCARE LIMITED, ("ABH" OR THE "OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●]/- PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM) OF ₹ [●] /- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [●] LAKHS (THE "ISSUE"), OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹[●]/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹ [●]/- PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "*MARKET MAKER RESERVATION PORTION*"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹ [●]/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹ [●]/- PER EQUITY SHARE AGGREGATING TO ₹[●] LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [●] % AND [●] %, RESPECTIVELY, OF THE POST-ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

*Subject to finalization of basis of allotment

This second addendum dated June 15, 2026 ("*Addendum*") should be read in conjunction with the Draft Red Herring Prospectus ("DRHP") and Addendum dated June 27, 2025 and November 28, 2025 respectively filed with Emerge Platform of the National Stock Exchange of India Limited ("NSE EMERGE") in relation to the Initial Public Offer of ABH Healthcare Limited.

1. The Draft Red Herring Prospectus contained the Restated Consolidated Financial Statements as at and for the nine months ended December 31, 2024 and the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022. The sections titled "**Restated Consolidated Financial Statements**" on pages 182, respectively of the DRHP have been updated to provide recent restated financial information of our Company, as at and for the nine months ended December 31, 2025 and the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 and the summary of material accounting policies and explanatory notes, prepared in accordance with Section 26 of Part I of Chapter III of the Companies Act, 2013, the SEBI ICDR Regulations, and the Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the ICAI, through this Addendum. All details in the sections titled, "**Restated Consolidated Financial Statements**" from this Addendum will be disclosed appropriately in the Red Herring Prospectus and the Prospectus, as and when filed with the RoC, the SEBI and the Stock Exchange.

2. The section titled "**Basis for Issue Price**" on page 102 of the DRHP has been updated to include details of updated relevant portions for Restated Consolidated Financial Statements as at and for the nine months ended December 31, 2025 and the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 and the Key Performance Indicators that our Company considers have a bearing for arriving at the Basis for Issue Price.

In order to assist the Bidders to get an understanding of the updated information, the updated relevant portions of the section titled “**Basis for Issue Price**” on page 102 of the DRHP, has been included in this Addendum.

The above changes are to be read in conjunction with the DRHP and accordingly their references in the DRHP stand updated pursuant to this Addendum. The information in this Addendum supplements the DRHP and updates the information in the DRHP, as applicable. Please note that the changes pursuant to this Addendum will be appropriately included in the Red Herring Prospectus and Prospectus, as and when filed with the RoC, the SEBI and the Stock Exchange.

All capitalized terms used in this Addendum shall unless the context otherwise requires, have the meaning ascribed to them in the Draft Red Herring Prospectus.

Place: Ferozepur

Date: June 15, 2026

For ABH Healthcare Limited
on behalf of the Board of Directors

Sd/-
Dr. Kamal Baghi
Chairman & Whole-time Director
DIN: 08449735

BOOK RUNNING LEAD MANAGER		REGISTRAR TO THE ISSUE	
			
FEDEX SECURITIES PRIVATE LIMITED B 7, 3rd Floor, Jay Chambers, Dayaldas Road, Vile Parle – [East], Mumbai- 400 057, Maharashtra, India Tel. Number: +91 81049 85249 Email Id: mb@fedsec.in Website: www.fedsec.in Contact Person: Karuna Bangera / Saipan Sanghvi SEBI Registration No.: INM000010163 Investors Grievance Id: investors@fedsec.in		BIGSHARE SERVICES PRIVATE LIMITED S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, next to Ahura Centre, Andheri East, Mumbai- 400093, Maharashtra, India Tel No: +91 22 62638200 Fax No: N.A. E-mail Id: ipo@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Id: investor@bigshareonline.com Contact Person: Mr. Sagar Pathare SEBI Registration No: INR000001385	
ISSUE PROGRAMME			
ANCHOR INVESTOR BID / ISSUE PERIOD⁽¹⁾:		BID/ISSUE OPENS ON*: [●]	BID/ISSUE CLOSES ON⁽²⁾⁽³⁾: [●]
[●]			

⁽¹⁾ Our Company, in consultation with the BRLM, may consider participation by Anchor Investors, in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date.

⁽²⁾ Our Company, in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date, in accordance with the SEBI ICDR Regulation.

⁽³⁾ The UPI mandate end time and date shall be at 4:00 p.m. on the Bid/Issue Closing Day.

TABLE OF CONTENTS

SECTION I – GENERAL	2
DEFINITIONS AND ABBREVIATIONS.....	2
SUMMARY OF FINANCIAL INFORMATION	3
BASIS FOR ISSUE PRICE.....	7
SECTION VI: RESTATED FINANCIAL INFORMATION	14
RESTATED CONSOLIDATED FINANCIAL STATEMENTS.....	14
CAPITALISATION STATEMENT.....	52
DECLARATION.....	53

SECTION I – GENERAL
DEFINITIONS AND ABBREVIATIONS

CORPORATE RELATED TERMS

Term	Description
“Second Addendum”	The second addendum dated June 15, 2026 to the Draft Red Herring Prospectus.
“Restated Consolidated Financial Information” / “Restated Consolidated Financial Statements”	The restated consolidated financial statements of our Company for the nine months period ended December 31, 2025, and for the Fiscal 2025, Fiscal 2024 and Fiscal 2023 which comprises of the restated consolidated balance sheet, restated consolidated statement of profit and loss and the restated consolidated cash flow statement, together with the annexures and notes thereto disclosed in the section titled “ <i>Restated Consolidated Financial Information</i> ” on page 182 of the Draft Red Herring Prospectus.

EXPLANATION OF KPI METRICS:

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
Growth in Revenue from Operations	Growth in Revenue from Operations provides information regarding the growth of our business for respective periods
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
Restated Profit After Tax	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
Capital Employed	Capital employed is to measure how effectively a company utilizes its overall resources to generate profits
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders ‘funds.
RoCE%	ROCE provides how efficiently our Company generates earnings from the capital employed in the business.
Debt Equity Ratio	This gearing ratio compares shareholders’ equity to company debt to assess the company’s amount of leverage and financial stability.
Fixed Assets Turnover Ratio	This ratio is a financial metric that measures how effectively a company utilizes its long term assets to generate revenue.

SUMMARY OF FINANCIAL INFORMATION

The following table set forth summary financial information derived from the Restated Consolidated Financial Statements. The summary financial information presented below should be read in conjunction with ***“Restated Consolidated Financial Statements”*** and ***“Management’s Discussion and Analysis of Financial Condition and Results of Operations”*** on page 182 and 219 respectively of the Draft Red Herring Prospectus.

[The Remainder of this Page has intentionally been left blank]

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	Notes	As at	As at	As at	As at
			31.12.2025	31.03.2025	31.03.2024	31.03.2023
			Consolidated	Consolidated	Standalone	Standalone
A	<u>EQUITY AND LIABILITIES</u>					
I	<u>Shareholder's Funds</u>					
(a)	Share Capital	3	800.00	200.00	200.00	200.00
(b)	Reserves and Surplus	4	773.67	969.19	435.29	269.73
	Sub Total (I)		1,573.67	1,169.19	635.29	469.73
II	Minority Interests		1.21	0.80	-	-
III	<u>Non Current Liabilities</u>					
(a)	Long Term Borrowings	5	4,398.59	2,890.18	2,453.17	1,373.55
(b)	Deferred Tax Liabilities (Net)	6	166.59	130.83	72.43	42.07
(c)	Other Long Term Liabilities	7	160.00	35.00	50.00	-
(d)	Long Term Provisions	8	56.86	49.04	28.43	10.82
	Sub Total (III)		4,782.04	3,105.05	2,604.03	1,426.44
IV	<u>Current Liabilities</u>					
(a)	Short Term Borrowings	9	392.19	1,297.76	1,125.40	724.09
(b)	Trade Payables	10				
	- Due to MSME		93.91	59.99	23.55	57.57
	- Due to Other than MSME		735.26	617.72	533.65	433.47
(c)	Other Current Liabilities	11	352.89	139.76	212.57	184.63
(d)	Short Term Provisions	12	0.16	0.13	0.09	0.04
	Sub Total (IV)		1,574.41	2,115.36	1,895.26	1,399.80
	GRAND TOTAL (I + II + III + IV)		7,931.33	6,390.40	5,134.58	3,295.97
B	<u>ASSETS</u>					
V	<u>Non Current Assets</u>					
(a)	<u>Property, Plant and Equipment and Intangible Assets</u>	13				
	- Property, Plant and Equipment		3,575.20	3,658.94	3,375.31	2,265.02
	- Other Intangible Assets		2.61	3.96	5.76	7.56
	- Capital Work In Progress		53.00	-	-	62.76
	- Goodwill	14	5.01	5.01	-	-
(b)	Non Current Investments	15	179.94	28.61	12.07	-
(c)	Other Non Current Assets	16	11.26	32.36	29.61	20.77
	Sub Total (V)		3,827.02	3,728.88	3,422.75	2,356.11
VI	<u>Current Assets</u>					
(a)	Inventories	17	307.31	445.78	289.10	225.90
(b)	Trade Receivables	18	3,324.73	1,973.61	1,197.87	589.27
(c)	Cash and Cash Equivalents	19	218.52	61.10	1.61	15.16
(d)	Short Term Loans & Advances	20	103.31	44.91	39.73	21.29
(e)	Other Current Assets	21	150.44	136.12	183.52	88.24
	Sub Total (VI)		4,104.31	2,661.52	1,711.83	939.86
	GRAND TOTAL (V + VI)		7,931.33	6,390.40	5,134.58	3,295.97

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman

DIN - 08449735

Sd/-

Rajeev Aggarwal
Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director

DIN - 09088201

Sd/-

Rahul Sharma
Company Secretary

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	Notes	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
			Consolidated	Consolidated	Standalone	Standalone
I	<u>INCOME</u>					
(a)	Revenue from Operations	22	3,879.26	4,926.71	4,138.02	2,961.06
(b)	Other Income	23	3.87	5.02	1.45	-
	TOTAL INCOME		3,883.13	4,931.73	4,139.47	2,961.06
II	<u>EXPENSES</u>					
(a)	Cost of Materials Consumed	24	813.05	1,024.20	1,132.19	809.02
(b)	Employee Benefit Expenses	25	680.26	849.49	706.32	569.72
(c)	Finance Cost	26	316.72	371.10	295.70	132.99
(d)	Depreciation and Amortisation Expenses	27	172.61	210.41	174.25	155.88
(e)	Other Expenses	28	1,338.67	1,733.51	1,610.23	1,177.67
	TOTAL EXPENSES		3,321.31	4,188.71	3,918.69	2,845.28
III	Profit before Exceptional and Extraordinary Items and Tax (I - II)		561.82	743.02	220.78	115.78
IV	Exceptional & Extraordinary Items		-	-	-	-
V	Profit before Tax (III - IV)		561.82	743.02	220.78	115.78
VI	<u>Tax Expense</u>					
(a)	Current Tax		100.17	122.68	52.07	21.03
(b)	MAT Credit (Entitlement) / Used		21.00	27.24	(27.21)	(21.03)
(c)	Deferred Tax		35.76	58.40	30.36	44.07
(d)	Earlier Period Tax Adjustments		-	-	-	0.48
	Total Tax Expense		156.93	208.32	55.22	44.55
VII	Net Profit for the year		404.89	534.70	165.56	71.23
VIII	Net Profit for the year attributable to:					
(a)	Owners of the Parent Company		404.48	533.90	165.56	71.23
(b)	Minority Interests		0.41	0.80	-	-
IX	<u>Restated Earning Per Equity Share</u>	29				
(a)	Basic EPS (In ₹)		5.06	6.68	2.07	1.05
(b)	Diluted EPS (In ₹)		5.06	6.68	2.07	1.05

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman
DIN - 08449735

Sd/-

Rajeev Aggarwal
Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director
DIN - 09088201

Sd/-

Rahul Sharma
Company Secretary

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF CASHFLOWS

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
		Consolidated	Consolidated	Standalone	Standalone
I	<u>CASH FLOW FROM OPERATING ACTIVITIES</u>				
	Net Profit Before Tax	561.82	743.02	220.78	115.78
(a)	Add -				
1	Depreciation	172.61	210.41	174.25	155.88
2	Interest Cost	263.77	347.03	279.99	120.81
3	Contribution to Employee Benefit Funds	7.86	20.65	17.66	10.85
4	Loss on sale of PPE	-	-	74.29	1.90
(b)	Less -				
1	Interest Income	3.26	4.28	0.86	-
2	Profit on sale of PPE (net)	0.19	-	-	-
	Operating Profit before Working Capital Changes	1,002.61	1,316.83	766.11	405.22
(c)	<u>Adjustment for Working Capital Changes</u>				
1	(Increase) / Decrease in Trade Receivables	(1,351.12)	(774.87)	(608.60)	(566.36)
2	(Increase) / Decrease in Inventories	138.47	(156.68)	(63.20)	(25.00)
3	(Increase) / Decrease in Short Term Loans & Advances	(58.40)	(5.18)	(18.44)	(5.25)
4	(Increase) / Decrease in Other Assets	7.14	20.99	(16.26)	(8.06)
5	Increase / (Decrease) in Trade Payables	151.46	108.60	66.16	88.31
6	Increase / (Decrease) in Other Liabilities	338.50	(94.58)	74.97	47.89
7	Increase / (Decrease) in Provisions	-	-	-	(5.80)
	Cash Generated from Operations	228.66	415.11	200.74	(69.05)
(d)	Less - Taxes Paid (Net of Refunds)	121.53	60.69	111.93	85.90
	NET CASH FLOW GENERATED FROM / (USED IN) OPERATING ACTIVITIES	107.13	354.42	88.81	(154.95)
II	<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
(a)	Interest Income	3.26	0.90	0.07	-
(b)	(Increase) / Decrease in Investments	(151.33)	3.68	(12.07)	-
(c)	Investments in LLP (Net of Cash & Cash Equivalents received in acquisition of LLP's)	-	6.52	-	-
(d)	Proceeds from Sale of PPE	5.55	-	120.07	21.60
(e)	Purchase of PPE & Intangible Assets	(92.88)	(464.51)	(1,414.34)	(104.16)
(f)	Additions to Capital Work in Progress	(53.00)	-	-	(62.76)
	NET CASH FLOW USED IN INVESTING ACTIVITIES	(288.40)	(453.41)	(1,306.27)	(145.32)
III	<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
(a)	Proceeds from Issue of Share Capital	-	-	-	380.00
(b)	Net Proceeds / (Repayment) from Long Term Borrowings (incl. Current Maturities)	1,496.52	307.28	1,226.92	(36.03)
(c)	Net Proceeds / (Repayment) of Short Term Borrowings	(893.68)	192.35	254.01	71.45
(d)	Interest & Finance Charges Paid	(264.15)	(341.15)	(277.02)	(121.59)
	NET CASH FLOW GENERATED FROM FINANCING ACTIVITIES	338.69	158.48	1,203.91	293.83
	NET INCREASE IN CASH & CASH EQUIVALENTS (I + II + III)	157.42	59.49	(13.55)	(6.44)
	OPENING CASH AND CASH EQUIVALENTS	61.10	1.61	15.16	21.60
	CLOSING CASH AND CASH EQUIVALENTS	218.52	61.10	1.61	15.16

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman

DIN - 08449735

Sd/-

Rajeev Aggarwal

Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director

DIN - 09088201

Sd/-

Rahul Sharma

Company Secretary

BASIS FOR ISSUE PRICE

The Price Band will be determined by our Company, in consultation with the BRLM on the basis of the following qualitative and quantitative factors. The face value of the Equity Share is ₹ 10 per Equity Share. The face value of the Equity Shares is ₹ 10 each and the Issue Price is [●] times the face value at the lower end of the Price Band and [●] times the face value at the higher end of the Price Band.

Investors should refer chapters titled **“Risk Factors”, “Business Overview”, “Restated Consolidated Financial Statements” and “Management Discussion and Analysis of Financial Condition and Results of Operations”** on page 33, 130, 182 and 219 respectively of the Draft Red Herring Prospectus to get an informed view before making an investment decision. The trading price of the Equity shares of our Company could decline due to risk factors and you may lose all or part of your investments.

Qualitative Factors

Some of the qualitative factors, which form the basis for computing the price, are:

- a) Doctor led professional management team with proven execution capabilities;
- b) Delivering quality clinical care by attracting and retaining experienced and renowned clinicians;
- c) Diversified operations across clinical specialties, payor mix and hospitals;
- d) Robust operating infrastructure including information technology and modern equipments; and
- d) Track record of stable operating and financial performance and growth.

For further details, see **“Business Overview”** on page 130 of the Draft Red Herring Prospectus.

Quantitative Factors

Information presented below relating to the Company is based on the Restated Consolidated Financial Statements for the nine months period ended December 31, 2025, Fiscal 2025, Fiscal 2024 and Fiscal 2023. Some of the quantitative factors which form the basis or computing the price, are as follows:

1) Basic and Diluted Earnings per Share (EPS)

Particulars	Basic EPS and Diluted EPS	Weights
March 31, 2023	1.05	1
March 31, 2024	2.07	2
March 31, 2025	6.68	3
Weighted Average	4.21	
For the nine months period ended December 31, 2025*		
Basic & Diluted	5.06	

*Not Annualised

Note.

- i. The face value of each Equity Share is ₹ 10.
- ii. Basic and diluted Earnings per share calculations are in accordance with Indian GAAP and Accounting Standard as applicable and based on the Restated Financial Statement of our Company.
- iii. Basic and Diluted EPS = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / weighted average no. of equity shares outstanding during the year (Post effect of bonus) / period as per Restated Consolidated Financial Statement. Weighted average no. of equity shares are calculated after considering bonus Equity shares issued before date of signing of the Restated Consolidated Financial Statement.
- iv. Weighted Average EPS = Aggregate of Year wise weighted EPS divided by the Aggregate weights i.e. [(EPS *Weights) for each year / Total Weights].
- v. The above statement should be read with significant accounting policies and notes on Restated Consolidated Financial Information as appearing in the Restated Consolidated Financial Statements.
- vi. The above EPS is considered after inclusion of 60,00,000 bonus Equity Shares issued on April 29, 2025

2) Price to Earnings (P/E) ratio in relation to Issue Price ₹ [●] per Equity Share of ₹ 10 each fully paid up

Particulars	P/E ratio
P/E ratio based on Basic & Diluted EPS for the Fiscal 2025	[●]
P/E ratio based on Weighted Average	[●]
Industry Peer Group P/E ratio*	
Highest*	52.13
Lowest*	23.80
Average*	37.97

Source: BSE and NSE Website

* The figures for the peer group are for the year ended March 31, 2025 and are based on their respective standalone and consolidated financial statements, as the case may be filed with Stock Exchanges. CMP of the peer group is as per the closing price as on June 12, 2026 as available on the websites of the Stock Exchanges.

3) Return on Net worth (RoNW)

Return on Net Worth (RoNW) as per Restated Consolidated Financial Statements:

Particulars	RoNW (%)	Weights
March 31, 2023	30.23	1
March 31, 2024	30.33	2
March 31, 2025	59.75	3
Weighted Average	45.02	
As at December 31, 2025	29.70	

Note: Return on Net worth has been calculated as per the following formula:

- Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Average Net worth as restated as at year/period end.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.
- Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account as per Restated Consolidated Financial Statement.

4) Net Asset Value (NAV)

Particulars	(₹)
Net Asset Value per Equity Share as of December 31, 2025	19.58
Net Asset Value per Equity Share as of March 31, 2025	14.50
Net Asset Value per Equity Share after IPO	[●]
Issue Price per Equity Share	[●]

Notes:

- Net Asset Value per Equity Share is calculated as net worth attributable to equity shareholders as at the end of Financial period/year divided by the weighted average number of Equity Shares used in calculating basic earnings per share after considering bonus Equity Shares.

“Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account, if any”

- To be decided upon finalization of Issue Price per Equity Share.

5) Key Performance Indicators

The table below sets forth the details of s that our Company considers have a bearing for arriving at the basis for Issue Price. The key financial and operational metrics set forth above, have been approved and verified by the members of the Audit Committee pursuant to their resolution dated June 15, 2026. Further, the Audit Committee has on June 15, 2026 taken on record that other than the key financial and operational metrics set out below, our Company has not disclosed any other KPIs during the three years preceding the date of this second Addendum with its investors. The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help it in analyzing the growth of various verticals in comparison to our Company’s peers, and other relevant and material KPIs of the business of our Company that have a bearing for arriving at the Basis for Issue Price have been disclosed below. Additionally, the KPIs have been certified by our Statutory Auditors - M/s. G D Singhal & Associates, Chartered Accountants, vide their certificate June 15, 2026 and has been included in “**Material Contracts and Documents**” for Inspection on page 327 of the Draft Red Herring Prospectus.

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of our Company.

The KPIs of our Company have been disclosed in the chapters titled “**Business Overview**” and “**Management’s Discussion and Analysis of Financial Condition and Results of Operations – Key Performance Indicators**” on pages 130 and 219 respectively of the Draft Red Herring Prospectus. We have described and defined the KPIs, as applicable, in “**Definitions and Abbreviations**” on page 2 of the Draft Red Herring Prospectus.

Comparison of KPIs based on material additions or dispositions to our business

Our Company has not made any additions or dispositions to our business in the last three Fiscals and the nine months period ended December 31, 2025 except the following additions;

- Anil Baghi Hospital (sole proprietorship concern of Dr. Kamal Baghi)

b. Five Creeks Healthcare LLP (LLP with 90% capital interest)

c. ABH Clinics LLP (LLP with 90% capital interest)

Our Company has not undertaken material acquisition or disposition of assets / business for the periods that are covered by the KPIs and accordingly, no comparison of KPIs over time based on additions or dispositions to the business, have been provided.

Our Company confirms that it shall continue to disclose all the KPIs included in this chapter on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Key Performance Indicators of our Company based on the Restated Consolidated Financial Statements.

(₹ in lakhs)

Particulars	For the nine months period ended December 31, 2025*	Fiscal 2025	Fiscal 2024	Fiscal 2023
Revenue from Operations ⁽¹⁾	3,879.26	4,926.71	4,138.02	2,961.06
Growth in Revenue from Operations (%) ⁽²⁾	-	19.06	39.75	746.09
EBITDA (₹ in Lakhs) ⁽³⁾	1,047.28	1,319.51	689.28	404.65
EBITDA Margin (%) ⁽⁴⁾	27.00	26.78	16.66	13.67
Restated Profit After Tax	404.89	534.70	165.56	71.23
PAT Margin (%) ⁽⁵⁾	10.44	10.85	4.00	2.41
Net Worth ⁽⁶⁾	1,566.05	1,160.22	629.53	462.17
Capital Employed	6,533.03	5,488.98	4,284.64	2,603.02
ROE (%) ⁽⁷⁾	29.70	59.75	30.33	30.23
ROCE (%) ⁽⁸⁾	14.55	22.70	14.96	10.64
Debt - Equity Ratio ⁽⁹⁾	3.07	3.62	5.69	4.54
Fixed Assets Turnover Ratio ⁽¹⁰⁾	1.09	1.35	1.23	1.31

* Not Annualized

Notes:

(1) Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.

(2) Growth in Revenue from Operations (%) is calculated as Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.

(3) EBITDA is calculated as Profit before tax + Depreciation & amortisation + Finance Cost (incl. bank charges) – Other Income

(4) EBITDA Margin (%) is calculated as EBITDA divided by Revenue from Operations

(5) PAT Margin (%) is calculated as PAT for the period/year divided by Revenue from operations.

(6) Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.

(7) Return on Equity (%) refers to restated profit for the year/period attributable to equity shareholders of our Company divided by Average Net Worth.

(8) Return on Capital Employed is calculated as earnings before interest and taxes divided by Average Capital Employed. Capital Employed is calculated as total equity plus total debt and deferred tax liabilities minus intangible assets and deferred tax assets.

(9) Debt Equity Ratio: This is defined as total debt divided by total equity. Total debt is the sum of total current & non-current borrowings including interest accrued but not due; total equity means Net Worth i.e. the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account;

(10) Fixed Asset Turnover Ratio: This is defined as revenue from operations divided by total of net block property, plant & equipment. Figures for property, plant & equipment do not include capital work-in-progress and intangible assets.

-Earnings before interest and tax is calculated as restated profit / (loss) for the period / year plus total tax expense / (credit) plus finance costs reduced by other income.

Explanation of KPI Metrics:

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
Growth in Revenue from Operations	Growth in Revenue from Operations provides information regarding the growth of our business for respective periods
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
Restated Profit After Tax	Profit after tax provides information regarding the overall profitability of the business.

PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
Capital Employed	Capital employed is to measure how effectively a company utilizes its overall resources to generate profits
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders' funds.
RoCE%	ROCE provides how efficiently our Company generates earnings from the capital employed in the business.
Debt Equity Ratio	This gearing ratio compares shareholders' equity to company debt to assess the company's amount of leverage and financial stability.
Fixed Assets Turnover Ratio	This ratio is a financial metric that measures how effectively a company utilizes its long term assets to generate revenue.

Operational KPIs of the Company on standalone basis

Particulars	December 31, 2025	Fiscal 2025	Fiscal 2024	Fiscal 2023
Total Bed Capacity ⁽¹⁾	150	150	100	85
Approved Beds ⁽²⁾	150	150	100	100
Operational Beds ⁽³⁾	125	125	85	70
ICU Beds	70	70	49	38
IPD Volume	4,939	6,339	5,723	5,162
IPD Revenue (₹ in Lakhs)	3,182.69	4,090.44	3,476.03	2,376.89
OPD Volume	40,945	53,556	43,415	39,153
OPD Revenue (₹ in Lakhs)	381.40	544.55	462.45	474.13
Revenue from Operations	3,805.55	4,891.62	4,138.02	2,961.06
Bed Days Occupied ⁽⁴⁾	16,359	22,419	19,519	16,650
Average Bed Occupancy Rate (%) ⁽⁵⁾	48	49	63	65
Average Revenue per Occupied Bed ⁽⁶⁾	19,455	18,245	17,808	14,276
Average length of stay in hospitals ("ALOS") (in days) ⁽⁷⁾	3.31	3.54	3.41	3.23

Notes: -

(1) Total bed capacity is as at end of relevant financial year or accounting period, as the case may be and denotes the number of beds for which the civil structure has been planned for.

(2) Number of approved beds is the beds authorised/certified by the Punjab Pollution Control Board

(3) Number of operational beds are subset of approved beds and refers to such number which are kept in operational basis the decision of management.

(4) Bed days occupied means actual bed days in the relevant financial year or accounting period, as the case may be

(5) Average Bed occupancy rate is calculated by dividing the overall number of actual days occupied by the patients by total operational bed days

(6) Average Revenue per Occupied Bed is calculated as inpatient revenue from operations divided by actual bed days occupied during the period.

(7) Average Length of Stay is calculated as average number of days spent by admitted inpatients

(8) Revenue from Operations is based on Standalone Financial Information.

Comparison with industry peers

While our listed peers (mentioned below), like us, operate in the same industry and may have similar offerings, they derive significant portion of revenue. Our business may be different in terms of differing business models.

Particulars	ABH Healthcare Limited				Sangani Hospitals Limited ⁽¹⁾			Maitreya Medicare Limited ⁽¹⁾			Asarfi Hospital Limited ⁽¹⁾		
	December 31, 2025	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023
Revenue from operations	3,879.26	4,926.71	4,138.02	2,961.06	2118.52	1,567.62	1,566.79	4,666.20	4,776.30	3,938.00	12,056.57	8,440.04	7,070.33
Growth in Revenue from Operations%	-	19.06	39.75	746.09	35.14	0.05	52.36	(2.31)	21.29	(20.30)	42.85	19.37	8.42
EBITDA	1,047.28	1,319.51	689.28	404.65	245.06	307.41	305.11	488.21	622.88	722.76	2,354.79	1,605.09	1,377.14
EBITDA Margin%	27.00	26.78	16.66	13.67	11.57	19.61	19.47	10.46	13.04	18.35	19.53	19.02	19.48
PAT	404.89	534.70	165.56	71.23	259.38	269.69	148.37	187.24	317.12	422.65	1057.61	416.16	801.53
PAT Margin %	10.44	10.85	4.00	2.41	12.24	17.20	9.47	4.01	6.64	10.73	8.77	4.93	11.34
Net Worth	1,566.05	1,160.22	629.53	462.17	3608.57	3,349.19	1,797.29	3193.86	3,022.61	1,435.92	8,098.32	7,040.70	4,184.26
Capital Employed	6,533.03	5,488.98	4,284.64	2,603.02	3,617.10	3,357.72	1,807.37	3714.78	3,592.86	2,021.04	12,954.05	10,231.92	5,904.46
RoE%	29.70	59.75	30.33	30.23	7.46	10.48	12.91	6.02	14.23	35.33	13.97	7.41	24.87

Particulars	ABH Healthcare Limited				Sangani Hospitals Limited ⁽¹⁾			Maitreya Medicare Limited ⁽¹⁾			Asarfi Hospital Limited ⁽¹⁾		
	December 31, 2025	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2025	March 31, 2024	March 31, 2023
RoCE %	14.55	22.70	14.96	10.64	5.32	10.80	16.61	9.41	17.66	31.84	9.38	9.00	21.22
Debt - Equity Ratio	3.07	3.62	5.69	4.54	0.00	0.00	0.01	0.16	0.19	0.41	0.60	0.45	0.41
Fixed Assets Turnover Ratio	1.09	1.35	1.23	1.31	1.61	1.24	1.32	3.06	3.34	3.40	1.19	0.90	1.83
Net Cash from/ (used in) Operating Activities	107.13	354.42	88.81	(154.95)	234.58	336.91	229.43	505.68	(215.39)	163.81	(434.98)	2,607.41	(206.52)

Notes:

1. Financial and Non-GAAP information are based on consolidated audited financial statements, unless specified of peer companies filed with the Stock Exchanges and the information available on website
2. Financial information as on December 31, 2025 are not available for peer group companies.

6) Comparison of Accounting Ratios with Listed Industry Peers

Set forth below are the details of comparison of key performance of indicators with our listed industry peers:

Name of the company	Consolidated / Standalone	Current Market Price (CMP)	Revenue from Operations (₹ in Lakhs)	EPS (in ₹)		P/E Ratio	PAT margin (%)	RONW (%)	NAV (Per Share)	Face Value (in ₹)	Market cap to Revenue from operation
				Basic	Diluted						
ABH Healthcare Limited	Consolidated	[●]	4,926.71	6.68	6.68	[●]	10.85	59.75	14.50	10.00	[●]
Peer Group											
Sangani Hospitals Limited	Consolidated	44.75	2,118.52	1.88	1.88	23.80	12.24	7.46	26.19	10.00	2.70
Maitreya Medicare Limited	Consolidated	156.90	4,666.20	3.01	3.01	52.13	4.01	6.02	47.13	10.00	2.93
Asarfi Hospital Limited	Consolidated	229.20	12,056.57	5.37	5.37	42.68	8.77	13.97	41.16	10.00	2.46

Source: All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the annual reports/ financial results as available of the respective company for the year ended March 31, 2025 submitted to stock exchanges or on company's website as available on www.bseindia.com and www.nseindia.com

Notes:

- a) The figures ABH Healthcare Limited are based on the Restated Consolidated Financial Statements for the Fiscal 2025.
- b) Current market price (CMP) is the closing market price of the equity shares of the respective companies on NSE on June 12, 2026.
- d) Diluted EPS refers to the diluted earnings per share sourced from the annual reports/annual results as available of the respective company for the year ended March 31, 2025 submitted to stock exchanges
- e) NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.
- f) P/E Ratio for the peer has been computed based on the closing market price of respective equity shares as on June 12, 2026 sourced from website of Stock Exchange as divided by the Basic/diluted EPS as applicable.
- g) RoNW is computed as net profit after tax, as attributable to the owners of the Company divided by closing net worth. Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.

7) Weighted average cost of acquisition

- a. The price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on the primary/ new issue of Equity Shares or convertible securities (excluding Equity Shares issued under the ESOP Scheme and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of this Addendum, where such issuance is equal to or more than 5% of the fully diluted paid up share capital of our Company in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Transactions")

Except bonus issue of Equity Shares, there has been no issuance of Equity Shares or convertible securities, excluding issuance of bonus shares, during the 18 months preceding the date of this Addendum, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the Pre-Issue capital

before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

- b. Secondary sales / acquisitions of Equity Shares or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of this Addendum, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction/s), in a single transaction or multiple transactions combined together over a span of rolling 30 days (“Secondary Transactions”).

There have been no secondary sales / acquisitions of Equity Shares, other than gift or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of this Addendum, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction/s), in a single transaction or multiple transactions combined together over a span of rolling 30 days (“Secondary Transactions”).

- c. Since there are no eligible transaction of our Company reported in 8 (a) and 8 (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoter/ Promoter Group entities or Shareholders having the right to nominate director on the Board are a party to the transaction) not older than 3 years prior to the date of filing of this Addendum has been computed as under:

Date of Transfer	Name of Transferor	Name of Transferee/ Allotee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Per Equity Shares (₹)	Nature of transaction*	Nature of consideration	Total consideration (in ₹) (B)*
Primary Issuances								
April 29, 2025	N.A.	Dr. Saurabh Baghi	41,10,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Kamal Baghi	17,99,988	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Vaishali Saini	90,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mr. Hem Raj Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Rita Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Sukarma Khanna	3	10	NA	Bonus Issue	Other than Cash	N.A.
Total			59,99,997					N.A.
Weighted Average Cost of Acquisition (primary transactions)								-
Secondary Issuances								
Date of Transfer	Name of Transferor		Name of Transferee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Equity Shares (₹)	Nature of transaction*	Total consideration (₹)
March 31, 2024	Dr. Kamal Baghi		Dr. Saurabh Baghi	13,20,000	10	Nil	Transfer of Equity Shares by way of gift	N.A.
October 1, 2024	Dr. Kamal Baghi		Mr. Hem raj Saini	1	10	33	Transfer of Equity Shares	33.00
October 1, 2024	Dr. Kamal Baghi		Mrs. Rita Saini	1	10	33	Transfer of Equity Shares	33.00
October 1, 2024	Dr. Kamal Baghi		Mrs. Sukarma Khanna	1	10	33	Transfer of Equity Shares	33.00
Total				13,20,003				99.00
Weighted Average Cost of Acquisition (secondary transactions)								Negligible

d. *Weighted average cost of acquisition and Issue Price*

Type of Transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor Price* (i.e. ₹ [●])	Cap Price* (i.e. ₹ [●])
I. Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan / employee stock option scheme and issuance of bonus shares, during the 18 (eighteen) months preceding the date of filing of this Addendum, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
II. Weighted average cost of acquisition for last 18 (eighteen) months for secondary sale/acquisition of shares equity/convertible securities, where promoter/ promoter group entities or shareholder(s) having the right to nominate director(s) in the Board area party to the transaction, during the 18 months preceding the date of filing of this Addendum, where either acquisition nor sale is equal to or more than five percent of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	N.A.	N.A.	N.A.
III. Since there are no such transactions to report to under (I) and (II) above, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions where our Promoter/members of our Promoter Group or Shareholder(s) having the right to nominate director(s) on the Board of our Company, are a party to the transaction, during the three years prior to the date of filing of this Addendum irrespective of the size of the transaction, is as below.	N.A.	[●]	[●]
Type of transactions	WACA (in ₹)	Floor Price (in ₹)	Cap Price (in ₹)
a) WACA* of Equity Shares based on primary issuances undertaken during the three immediately preceding years.	N.A.	[●]	[●]
b) WACA* of Equity Shares based on secondary transactions under taken during the three immediately preceding years.	Negligible	N.A.	N.A.

* To be included upon finalization of the Price Band.

8) The Issue price is [●] times of the face value of the Equity Shares

The Issue Price of ₹ [●] has been determined by our Company in consultation with the BRLM, on the basis of market demand from investors for Equity Shares, as determined through the Book Building Process, and is justified in view of the above qualitative and quantitative parameters.

Prospective investors should read the above-mentioned information along with **“Risk Factors”**, **“Business Overview”**, **“Restated Consolidated Financial Statements”** and **“Management’s Discussion and Analysis of Financial Position and Results of Operations”** on page 33, 130,182 and 219 respectively of the Draft Red Herring Prospectus, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the **“Risk Factors”** on page 33 of the Draft Red Herring Prospectus and you may lose all or part of your investments.

SECTION VI: RESTATED FINANCIAL INFORMATION
RESTATED CONSOLIDATED FINANCIAL STATEMENTS

[The Remainder of this Page has intentionally been left blank]

INDEPENDENT AUDITORS' EXAMINATION REPORT ON RESTATED CONSOLIDATED FINANCIAL INFORMATION

To,
The Board of Directors
ABH Healthcare Limited
(formerly known as ABH Healthcare Private Limited)
Martyr Anil Baghi Road,
Firozpur

Dear Sirs / Madams,

1. We have examined the attached Restated Consolidated Financial Information of **ABH Healthcare Limited** *(formerly known as ABH Healthcare Private Limited)*, (the "Company" or the "Issuer") and its subsidiaries (the Company and its subsidiaries together referred to as the "Group"), comprising the Restated Consolidated Statement of Assets and Liabilities as at stub period ended December 31, 2025, and for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, the Restated Consolidated Statement of Profit and Loss and Restated Consolidated Statement of Cash Flows for the stub period ended December 31, 2025 and for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, and the Summary of Significant Accounting Policies and other explanatory information (collectively, the "Restated Consolidated Financial Information"), as approved by the Board of Directors of the Company at their meeting held on May 08, 2026 for the purpose of inclusion in the Draft Red Herring Prospectus ("DRHP") / Red Herring Prospectus ("RHP") / Prospectus (collectively, the "Offer Documents") prepared by the Company in connection with its proposed Initial Public Offer of equity shares ("IPO") and prepared in terms of the requirements of –
 - a) Section 26 of Part I of Chapter III of the Companies Act 2013 (the "Act"), as amended from time to time;
 - b) The Securities and Exchange Board of India ("SEBI") (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations"), as amended from time to time; and
 - c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time (the "Guidance Note").

Management's Responsibility for the Restated Summary Statements

2. The preparation of the Restated Consolidated Financial Information, which are to be included in the Offer Documents to be filed with SEBI, Registrar of Companies, Chandigarh ("ROC") and the Stock Exchanges in connection with the proposed IPO is the responsibility of the Management. The Restated Consolidated Financial Information have been prepared by the Management on the basis of preparation, as stated in Note 2.1 of the Restated Consolidated Financial Information. The Management's responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information. The Management is also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.

Auditors' Responsibilities

3. We have examined such Restated Consolidated Financial Information taking into consideration –
 - a) The terms of reference and terms of our engagement agreed with you vide our engagement letter dated April 26, 2025, requesting us to carry out the assignment, in connection with the proposed IPO of the Company;
 - b) The Guidance Note also requires that we comply with ethical requirements of the Code of Ethics Issued by ICAI;
 - c) Concepts of test checks and materiality to obtain reasonable assurance based on the verification of evidence

supporting the Restated Summary Statements; and

- d) the requirements of Section 26 of the Act and the ICDR Regulations.

Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO.

Restated Summary Statements

- 4. These Restated Consolidated Summary Statements have been compiled by the management from –
 - a) Audited Special Purpose Interim Consolidated IGAAP Financial Statements of the Group as at and for the stub period ended December 31, 2025 which were prepared in accordance with the Accounting Standards (referred to as “AS”) as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on May 01, 2026.
 - b) Audited Consolidated IGAAP Financial Statements of the Company as at and for the year ended March 31, 2025 which were prepared in accordance with the Accounting Standards (referred to as “AS”) as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on October 15, 2025.
 - c) Audited IGAAP Financial Statements of the Company as at and for the year ended March 31, 2024 which were prepared in accordance with the Accounting Standards (referred to as “AS”) as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on September 16, 2024.
 - d) Audited IGAAP Financial Statements of the Company as at and for the year ended March 31, 2023 which were prepared in accordance with the Accounting Standards (referred to as “AS”) as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on August 02, 2023.

Auditor’s Report

- 5. For the purpose of our examination, we have relied on:
 - a) Auditors’ Report issued by us, dated May 01, 2026, on the Audited Special Purpose Interim Consolidated IGAAP Financial Statements of the Group as at and for the stub period ended December 31, 2025 as referred in Paragraph 4(a) above.
 - b) Auditors’ Report issued by us, dated October 15, 2025, on the Audited Consolidated IGAAP Financial Statements of the Company as at and for the year ended March 31, 2025, as referred in Paragraph 4(b) above.
 - c) Auditors’ Report issued by us, dated September 16, 2024, on the Audited IGAAP Financial Statements of the Company as at and for the year ended March 31, 2024, as referred in Paragraph 4(c) above.
 - d) Auditors’ Reports issued by M/s Gagan Deep Singhal & Associates, Chartered Accountants, (the “Previous Auditors”), dated August 02, 2023, on the Audited IGAAP Financial Statements of the Company as at and for the year ended March 31, 2023, as referred in Paragraph 4(d) above.
- 6. Based on our examination and according to the information and explanations given to us, we report that Restated Consolidated Financial Information of the Company –
 - a) have been prepared after incorporating necessary adjustments for the changes in accounting policies, material errors and regrouping / reclassifications retrospectively in the financial year ended March 31, 2025, March

31, 2024, and March 31, 2023 to reflect the same accounting treatment as per the accounting policies and grouping / classifications, to the extent applicable followed as at and for the period ended December 31, 2025;

- b) does not contain any qualification requiring adjustments.
 - c) have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.
7. These Restated Consolidated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates for the special purpose Audited Interim Financial Statements and Audited Financial Statements mentioned in the paragraph 4 above.
 8. This report should not in any way be construed as a reissuance or re-dating of any of the previous audit reports issued by us and the Previous Auditors, nor should this report be construed as a new opinion on any of the financial statements referred to herein.
 9. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
 10. Our report is intended solely for the use of the Board of Directors for inclusion in the Offer Documents to be filed with SEBI, ROC and the Stock Exchanges in connection with the proposed IPO. Our report should not be used, referred to, or distributed for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. – 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. – 098947

UDIN – 26098947URLELT7013

Firozpur

May 08, 2026

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	Notes	As at	As at	As at	As at
			31.12.2025	31.03.2025	31.03.2024	31.03.2023
			Consolidated	Consolidated	Standalone	Standalone
A	<u>EQUITY AND LIABILITIES</u>					
I	<u>Shareholder's Funds</u>					
(a)	Share Capital	3	800.00	200.00	200.00	200.00
(b)	Reserves and Surplus	4	773.67	969.19	435.29	269.73
	Sub Total (I)		1,573.67	1,169.19	635.29	469.73
II	Minority Interests		1.21	0.80	-	-
III	<u>Non Current Liabilities</u>					
(a)	Long Term Borrowings	5	4,398.59	2,890.18	2,453.17	1,373.55
(b)	Deferred Tax Liabilities (Net)	6	166.59	130.83	72.43	42.07
(c)	Other Long Term Liabilities	7	160.00	35.00	50.00	-
(d)	Long Term Provisions	8	56.86	49.04	28.43	10.82
	Sub Total (III)		4,782.04	3,105.05	2,604.03	1,426.44
IV	<u>Current Liabilities</u>					
(a)	Short Term Borrowings	9	392.19	1,297.76	1,125.40	724.09
(b)	Trade Payables	10				
	- Due to MSME		93.91	59.99	23.55	57.57
	- Due to Other than MSME		735.26	617.72	533.65	433.47
(c)	Other Current Liabilities	11	352.89	139.76	212.57	184.63
(d)	Short Term Provisions	12	0.16	0.13	0.09	0.04
	Sub Total (IV)		1,574.41	2,115.36	1,895.26	1,399.80
	GRAND TOTAL (I + II + III + IV)		7,931.33	6,390.40	5,134.58	3,295.97
B	<u>ASSETS</u>					
V	<u>Non Current Assets</u>					
(a)	<u>Property, Plant and Equipment and Intangible Assets</u>	13				
	- Property, Plant and Equipment		3,575.20	3,658.94	3,375.31	2,265.02
	- Other Intangible Assets		2.61	3.96	5.76	7.56
	- Capital Work In Progress		53.00	-	-	62.76
	- Goodwill	14	5.01	5.01	-	-
(b)	Non Current Investments	15	179.94	28.61	12.07	-
(c)	Other Non Current Assets	16	11.26	32.36	29.61	20.77
	Sub Total (V)		3,827.02	3,728.88	3,422.75	2,356.11
VI	<u>Current Assets</u>					
(a)	Inventories	17	307.31	445.78	289.10	225.90
(b)	Trade Receivables	18	3,324.73	1,973.61	1,197.87	589.27
(c)	Cash and Cash Equivalents	19	218.52	61.10	1.61	15.16
(d)	Short Term Loans & Advances	20	103.31	44.91	39.73	21.29
(e)	Other Current Assets	21	150.44	136.12	183.52	88.24
	Sub Total (VI)		4,104.31	2,661.52	1,711.83	939.86
	GRAND TOTAL (V + VI)		7,931.33	6,390.40	5,134.58	3,295.97

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman

DIN - 08449735

Sd/-

Rajeev Aggarwal
Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director

DIN - 09088201

Sd/-

Rahul Sharma
Company Secretary

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	Notes	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
			Consolidated	Consolidated	Standalone	Standalone
I	<u>INCOME</u>					
(a)	Revenue from Operations	22	3,879.26	4,926.71	4,138.02	2,961.06
(b)	Other Income	23	3.87	5.02	1.45	-
	TOTAL INCOME		3,883.13	4,931.73	4,139.47	2,961.06
II	<u>EXPENSES</u>					
(a)	Cost of Materials Consumed	24	813.05	1,024.20	1,132.19	809.02
(b)	Employee Benefit Expenses	25	680.26	849.49	706.32	569.72
(c)	Finance Cost	26	316.72	371.10	295.70	132.99
(d)	Depreciation and Amortisation Expenses	27	172.61	210.41	174.25	155.88
(e)	Other Expenses	28	1,338.67	1,733.51	1,610.23	1,177.67
	TOTAL EXPENSES		3,321.31	4,188.71	3,918.69	2,845.28
III	Profit before Exceptional and Extraordinary Items and Tax (I - II)		561.82	743.02	220.78	115.78
IV	Exceptional & Extraordinary Items		-	-	-	-
V	Profit before Tax (III - IV)		561.82	743.02	220.78	115.78
VI	<u>Tax Expense</u>					
(a)	Current Tax		100.17	122.68	52.07	21.03
(b)	MAT Credit (Entitlement) / Used		21.00	27.24	(27.21)	(21.03)
(c)	Deferred Tax		35.76	58.40	30.36	44.07
(d)	Earlier Period Tax Adjustments		-	-	-	0.48
	Total Tax Expense		156.93	208.32	55.22	44.55
VII	Net Profit for the year		404.89	534.70	165.56	71.23
VIII	Net Profit for the year attributable to:					
(a)	Owners of the Parent Company		404.48	533.90	165.56	71.23
(b)	Minority Interests		0.41	0.80	-	-
IX	<u>Restated Earning Per Equity Share</u>	29				
(a)	Basic EPS (In ₹)		5.06	6.68	2.07	1.05
(b)	Diluted EPS (In ₹)		5.06	6.68	2.07	1.05

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman
DIN - 08449735

Sd/-

Rajeev Aggarwal
Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director
DIN - 09088201

Sd/-

Rahul Sharma
Company Secretary

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

RESTATED CONSOLIDATED STATEMENT OF CASHFLOWS

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
		Consolidated	Consolidated	Standalone	Standalone
I	<u>CASH FLOW FROM OPERATING ACTIVITIES</u>				
	Net Profit Before Tax	561.82	743.02	220.78	115.78
(a)	Add -				
1	Depreciation	172.61	210.41	174.25	155.88
2	Interest Cost	263.77	347.03	279.99	120.81
3	Contribution to Employee Benefit Funds	7.86	20.65	17.66	10.85
4	Loss on sale of PPE	-	-	74.29	1.90
(b)	Less -				
1	Interest Income	3.26	4.28	0.86	-
2	Profit on sale of PPE (net)	0.19	-	-	-
	Operating Profit before Working Capital Changes	1,002.61	1,316.83	766.11	405.22
(c)	<u>Adjustment for Working Capital Changes</u>				
1	(Increase) / Decrease in Trade Receivables	(1,351.12)	(774.87)	(608.60)	(566.36)
2	(Increase) / Decrease in Inventories	138.47	(156.68)	(63.20)	(25.00)
3	(Increase) / Decrease in Short Term Loans & Advances	(58.40)	(5.18)	(18.44)	(5.25)
4	(Increase) / Decrease in Other Assets	7.14	20.99	(16.26)	(8.06)
5	Increase / (Decrease) in Trade Payables	151.46	108.60	66.16	88.31
6	Increase / (Decrease) in Other Liabilities	338.50	(94.58)	74.97	47.89
7	Increase / (Decrease) in Provisions	-	-	-	(5.80)
	Cash Generated from Operations	228.66	415.11	200.74	(69.05)
(d)	Less - Taxes Paid (Net of Refunds)	121.53	60.69	111.93	85.90
	NET CASH FLOW GENERATED FROM / (USED IN) OPERATING ACTIVITIES	107.13	354.42	88.81	(154.95)
II	<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
(a)	Interest Income	3.26	0.90	0.07	-
(b)	(Increase) / Decrease in Investments	(151.33)	3.68	(12.07)	-
(c)	Investments in LLP (Net of Cash & Cash Equivalents received in acquisition of LLP's)	-	6.52	-	-
(d)	Proceeds from Sale of PPE	5.55	-	120.07	21.60
(e)	Purchase of PPE & Intangible Assets	(92.88)	(464.51)	(1,414.34)	(104.16)
(f)	Additions to Capital Work in Progress	(53.00)	-	-	(62.76)
	NET CASH FLOW USED IN INVESTING ACTIVITIES	(288.40)	(453.41)	(1,306.27)	(145.32)
III	<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
(a)	Proceeds from Issue of Share Capital	-	-	-	380.00
(b)	Net Proceeds / (Repayment) from Long Term Borrowings (incl. Current Maturities)	1,496.52	307.28	1,226.92	(36.03)
(c)	Net Proceeds / (Repayment) of Short Term Borrowings	(893.68)	192.35	254.01	71.45
(d)	Interest & Finance Charges Paid	(264.15)	(341.15)	(277.02)	(121.59)
	NET CASH FLOW GENERATED FROM FINANCING ACTIVITIES	338.69	158.48	1,203.91	293.83
	NET INCREASE IN CASH & CASH EQUIVALENTS (I + II + III)	157.42	59.49	(13.55)	(6.44)
	OPENING CASH AND CASH EQUIVALENTS	61.10	1.61	15.16	21.60
	CLOSING CASH AND CASH EQUIVALENTS	218.52	61.10	1.61	15.16

As per our report of even date attached separately

For G. D. Singhal & Associates

Chartered Accountants

Firm Registration No. - 017648N

Sd/-

Gagan Deep Singhal

Partner

Membership No. - 098947

Firozpur

May 8, 2026

For and on behalf of Board

Sd/-

Kamal Baghi

Chairman

DIN - 08449735

Sd/-

Rajeev Aggarwal

Chief Financial Officer

Sd/-

Saurabh Baghi

Managing Director

DIN - 09088201

Sd/-

Rahul Sharma

Company Secretary

1. GENERAL INFORMATION

- (i) ABH Healthcare Limited ("the Company") is a Limited Company domiciled in India and incorporated on March 02, 2021 under the provision of Companies Act, 2013 as Private Limited Company vide CIN – U85300PB2021PTC052886. The company was converted to Public Limited Company vide CIN – U85300PB2021PLC052886 on November 15, 2024. The registered office of Company is located at Martyr Anil Baghi Road, Firozpur – 152 002 (Punjab).
- (ii) The Company is engaged in the business of establishing, maintaining, assisting healthcare services in India, in the form of Super Speciality Hospitals and Allied Services such as Laboratories & Diagnostic Centres, Blood Bank and other related services.

2. SIGNIFICANT ACCOUNTING POLICIES

2.1 BASIS FOR PREPARATION OF FINANCIAL STATEMENTS

The Restated Consolidated Financial Information comprises of the Restated Consolidated Statement of Assets and Liabilities of the Company as at December 31, 2025, March 31, 2025, March 31, 2024 and March 31, 2023, the Restated Consolidated Statement of Profit and Loss, the Restated Consolidated Statement of Cash Flows for each of the period ended December 31, 2025, March 31, 2025, March 31, 2024 and March 31, 2023, and the summary of Significant Accounting Policies and explanatory Notes to the Restated Financial Statements (Collectively the "Restated Consolidated Financial Information")

These Restated Consolidated Financial Information have been prepared in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time, issued by the Securities and Exchange Board of India ("SEBI") on September 11, 2018, in pursuance of the Securities and Exchange Board of India Act, 1992 ("ICDR Regulations") for the purpose of inclusion in the Draft Red Herring Prospectus ("DRHP") / Red Herring Prospectus ("RHP") / Prospectus (collectively, the "Offer Documents") in connection with proposed Initial Public Offer of equity shares ("IPO") and prepared in terms of the requirements of –

- (i) Section 26 of Part I of Chapter III of the Companies Act 2013 (the "Act"), as amended from time to time.
- (ii) The Securities and Exchange Board of India ("SEBI") (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations"), as amended from time to time; and

- (iii) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time (the "Guidance Note")

These Consolidated Restated Summary Statements have been compiled by the management from –

- (i) Audited Special Purpose Interim Consolidated IGAAP Financial Statements of the Group as at and for the stub period ended December 31, 2025 which were prepared in accordance with the Accounting Standards (referred to as "AS") as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on May 01, 2026.
- (ii) Audited Consolidated IGAAP Financial Statements of the Company as at and for the year ended March 31, 2025 which were prepared in accordance with the Accounting Standards (referred to as "AS") as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on October 15, 2025.
- (iii) Audited IGAAP Financial Statements of the Company as at and for the year ended March 31, 2024 and March 31, 2023 which were prepared in accordance with the Accounting Standards (referred to as "AS") as prescribed under Section 133 of the Act read with Companies (Accounts) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India, at the relevant time, which have been approved by the Board of Directors at their meeting held on September 16, 2024 and August 02, 2023, respectively.

The accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

2.2 SYSTEM OF ACCOUNTING

The company follows mercantile system of accounting and recognizes income and expenditure on the accrual basis except those with significant uncertainties. Financial Statements are based on historical cost. These

costs are adjusted to reflect the impact of the changing value in the purchasing power of the company.

2.3 FUNCTIONAL AND PRESENTATION CURRENCY

The functional currency of the company is Indian Rupee (₹). These financial statements are presented in Indian Rupee (₹), and all values are rounded to the nearest **Lakhs** (1,00,000) except wherever otherwise stated.

2.4 USE OF ESTIMATES

The preparation of financial statements is in conformity with the generally accepted accounting principles; require estimates and assumptions to be made that affect the reported amount of assets and liabilities as of the date of the financial statements and the reported amounts of revenues & expenses during the reported period and disclosure of contingent liabilities & assets. The estimates and assumption used in the accompanying financial statements are based upon management's evaluation of the relevant facts and circumstances as of the date of financial statements. Actual result may differ from the estimates and assumptions used in preparing the accompanying financial statements. Differences between the actual results and estimates are recognized in the period in which the results are known / materialized.

2.5 PROPERTY, PLANT AND EQUIPMENT

(i) Recognition and Measurement

Property, Plant and Equipment are stated at cost, net of accumulated depreciation (other than freehold land) and impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and direct cost which are attributable for bringing the asset to its working condition. Capitalisation of costs in the carrying amount of property, plant and equipment ceases when the item is in the location and condition necessary for it to be capable of operating in the manner intended by the Company. Any trade discounts and rebates are deducted in arriving at the purchase price.

The Company identifies and determines cost of each component / part of the asset separately, if the component / part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset. These components are depreciated separately over their useful lives; the remaining components are depreciated over the life of the principal asset.

(ii) Subsequent Costs

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of

performance. Incomes and expenses related to the incidental operations not necessary to bring the item to the location and the condition necessary for it to be capable of operating in the manner intended by the Company are recognised in the Statement of profit and loss. All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the Statement of Profit & Loss for the period / year in which such expenses are incurred.

(iii) Capital Work in Progress

Capital work-in-progress comprises of property, plant and equipment that are not ready for their intended use at the end of reporting period and are carried at cost comprising direct costs, related incidental expenses, other directly attributable costs and borrowing costs.

(iv) Disposal

An item of property, plant and equipment is derecognised upon disposal or when no future benefits are expected from its use or disposal. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised net within other income / expenses in the statement of profit and loss.

(v) Depreciation

Depreciation is provided on Straight Line Method at the rates and in accordance with Schedule II to the Companies Act, 2013 and pro-rata depreciation is charge in respect of additions to fixed assets during the year. The company has assessed the useful life of all assets of the company in accordance with the Schedule II of the Companies Act, 2013 and simultaneously the depreciation has been calculated keeping in view the relevant applicable provisions of the Schedule II of Companies Act, 2013. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at regular intervals and adjusted prospectively, if appropriate.

2.6 INTANGIBLE ASSETS

(i) Recognition and Measurement

Intangible assets are recognised when the asset is identifiable, is within the control of the Company, it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the asset can be reliably measured.

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets acquired by the Company that have finite useful lives are measured at cost less accumulated amortisation and any accumulated impairment losses.

(ii) Subsequent Measurement

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.

(iii) Amortisation

Amortisation is calculated over the cost of the asset, or other amount substituted for cost. Amortisation is recognised in statement of profit and loss on a straight - line basis over the best estimated useful lives of intangible assets from the date that they are available for use.

The company has considered the useful life of the Computer Software as 5 years.

(iv) Disposal

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

2.7 BORROWING COST

Specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of the asset. Other borrowing costs are recognized as expenses in the period in which they are incurred.

2.8 INVESTMENTS

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

Current Investments are valued at lower of Cost and Fair Value, computed category wise. Non-Current Investments are valued at Cost. However, a provision for decline is recognised in case of permanent diminution in the value of non-current investments.

2.9 INVENTORY VALUATION

Inventory of Medical consumables and drugs, Stores and spares are valued at lower of cost and net realizable value.

The inventory cost is inclusive of purchase price and other incidental expenses which are directly attributable to bring the inventory at its present location for future use. Cost is determined on FIFO Basis.

Net realisable value is the estimated selling price in the ordinary course of business determined on the expected selling date; less estimated costs necessary to make the sale.

2.10 CASH AND CASH EQUIVALENTS

Cash and Cash Equivalents include cash in hand, bank balances, deposits with bank (other than on lien) and all short term and highly liquid investments that are readily convertible into known amounts of cash and are subject to an insignificant risk of change in value.

2.11 GST CREDIT

Input credit of GST on inputs, capital assets and input services are recognized in accordance with the Goods & Service Tax Act.

2.12 PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

Provision is recognized (for liabilities that can be measured by using a substantial degree of estimation) when –

- a) The company has a present obligation because of a past event.
- b) A probable outflow of resources embodying economic benefits is expected to settle the obligation; and
- c) The amount of the obligation can be reliably estimated.

Contingent liability is disclosed in case there is –

- (i) Possible obligation that arises from past events and existence of which will be confirmed only by the occurrence or non – occurrence of one or more uncertain future events not wholly within the control of the enterprise; or
- (ii) A present obligation arising from past events but is not recognized –
 - When it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
 - A reliable estimate of the amount of the obligation cannot be made.

Contingent Assets are neither disclosed nor recognised.

2.13 REVENUE RECOGNITION

- (i) The company derives its revenues primarily from healthcare services and other ancillary activities. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured in accordance with AS-9, Revenue Recognition. Sales are recognized on accrual basis, and only after transfer of services to the customer.

(ii) Other Operating Income

Other Operating Income represents the income received / to be received by the company from its outsourced partner to whom such service has been outsourced. The company recognises such income when the owners right to receive payment is established.

(iii) **Interest Income**

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

(iv) **Insurance & Other Claims**

Revenue in respect of claims is recognized when no significant uncertainty exists with regard to the amount to be realized and the ultimate collection thereof.

(v) **Other Income**

Other items of income and expenditure are recognized on accrual basis and as a going concern basis, and the accounting policies are consistent with the generally accepted accounting policies.

2.14 EXPENSES

Goods received are accounted as purchases on satisfactory completion of inspection. Other expenses and price escalation to suppliers, if any, to the extent not settled at the balance sheet date are accounted based on reasonable estimates made after considering negotiations with vendors / customers.

2.15 EMPLOYEE BENEFITS

Expenses and Liabilities in respect of employee benefits are recorded in accordance with Accounting Standard 15 – Employee Benefits (Revised 2005) “Revised AS 15”.

(i) **Short Term Employee Benefits**

Short Term Employee Benefits are recognized as an expense on an undiscounted basis in the Profit & Loss Account of the year in which the amount for the related service is actually paid.

(ii) **Post Employment Benefits**

- **Defined Contribution Plans**
Provident Fund

Contributions to the provident fund, which is defined contribution scheme, are recognised as an employee benefit expense in the statement of profit and loss in the period in which the contribution is due. Contributions are made in accordance with the rules of the statute and are recognised as expenses when employees render service entitling them to the contributions.

- **Defined Benefit Plans**
Gratuity

The employees’ gratuity scheme is a defined benefit obligation and is unfunded. The present value of the obligation under such defined benefit plans is determined based on actuarial valuation using the projected unit credit method, which recognises each period of service as giving rise to additional unit of employee benefit entitlement and

measures each unit separately to build up the final obligation.

The obligation is measured at the present value of the estimated future cash flows. The discount rates used for determining the present value of the obligation under defined benefit plans, is based on the market yields on government securities as at the reporting date, having maturity periods approximating to the terms of related obligations.

When the benefits of the plan are changed or when a plan is curtailed, the resulting change in benefits that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of profit and loss. Net interest is calculated by applying the discount rate to the net defined benefit liability. The Company recognises gains / losses on settlement of a defined plan when the settlement occurs.

2.16 ACCOUNTING FOR TAXES ON INCOME

(i) Income Tax Expenses comprise of Current Tax and Deferred Tax.

(ii) Current Tax for current and prior periods is recognized at the amount expected to be paid to or recovered by the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date.

(iii) Deferred Tax Assets and Liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. A deferred income tax asset is recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilized. The Company offers current tax assets and current tax liabilities, where it has legally enforceability and where it intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

2.17 EARNING PER SHARE

(i) Basic Earnings per Share are computed by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the period.

(ii) Diluted Earnings per Share is computed by taking into account weighted average number of equities share outstanding during the period and weighted average

number of Equity Share could have been issued upon conversion of all the Dilutive Potential Equity Shares into Equity Shares. Dilutive Potential Equity Shares are deemed converted as of the beginning of the period, unless issued at later date. Dilutive Potential Equity Shares are determined independently for each period presented.

2.18 CASH FLOW STATEMENT

Cash Flows are reported using the indirect method, whereby net profit / loss before tax is adjusted for the effects of transactions of non-cash nature, any deferrals of accruals of past or future operating cash receipts or payments and item of income or expense associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

3 SHARE CAPITAL

S. No.	Particulars	As at 31.12.2025		As at 31.03.2025	
		No. of shares	Amount	No. of shares	Amount
1	Authorised Share Capital*				
(a)	Equity Shares of ₹10/- each	1,30,00,000	1,300.00	1,30,00,000	1,300.00
2	Issued, Subscribed, Called and Paid up Capital				
(a)	Equity Shares of ₹10/- each	80,00,000	800.00	20,00,000	200.00

S. No.	Particulars	As at 31.03.2024		As at 31.03.2023	
		No. of shares	Amount	No. of shares	Amount
1	Authorised Share Capital*				
(a)	Equity Shares of ₹10/- each	40,00,000	400.00	40,00,000	400.00
2	Issued, Subscribed, Called and Paid up Capital				
(a)	Equity Shares of ₹10/- each	20,00,000	200.00	20,00,000	200.00

* The Authorised Capital has been increased to ₹1,300.00 Lakhs divided into 1,30,00,000 equity shares of ₹10 each w.e.f. February 12, 2025.

3.1 The reconciliation of the number of paid up shares outstanding is set out below

S. No.	Particulars	As at 31.12.2025		As at 31.03.2025	
		No. of shares	Amount	No. of shares	Amount
1	Equity Shares at the beginning	20,00,000	200.00	20,00,000	200.00
2	Add - Shares issued during the period*	60,00,000	600.00	-	-
3	Less - Shares cancelled on buy back	-	-	-	-
4	Equity Shares at the end of the period	80,00,000	800.00	20,00,000	200.00

* The Paid Up Capital has been increased to ₹800.00 Lakhs divided into 80,00,000 equity shares of ₹10 each w.e.f. April 29, 2025 by issuing additional 60,00,000 bonus equity shares of ₹10 each aggregating to ₹600.00 Lakhs.

S. No.	Particulars	As at 31.03.2024		As at 31.03.2023	
		No. of shares	Amount	No. of shares	Amount
1	Equity Shares at the beginning	20,00,000	200.00	1,00,000	10.00
2	Add - Shares issued during the period	-	-	19,00,000	190.00
3	Less - Shares cancelled on buy back	-	-	-	-
4	Equity Shares at the end of the period	20,00,000	200.00	20,00,000	200.00

3.2 Aggregate number of bonus shares issued during the period of five years immediately preceding the reporting date

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Equity shares allotted as fully paid bonus shares by capitalization of Reserves & Surplus	60,00,000	-	-	-

3.3 Details of Shareholders holding more than 5% shares

S. No.	Name of the Shareholder	As at 31.12.2025		As at 31.03.2025	
		No. of Shares	% held	No. of shares	% held
1	Kamal Baghi	23,99,984	30.00	5,99,996	30.00
2	Saurabh Baghi	54,80,000	68.50	13,70,000	68.50
	Total	78,79,984	98.50	19,69,996	98.50

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Name of the Shareholder	As at 31.03.2024		As at 31.03.2023	
		No. of Shares	% held	No. of shares	% held
1	Kamal Baghi	6,00,000	30.00	19,20,000	96.00
2	Saurabh Baghi	13,70,000	68.50	50,000	2.50
	Total	19,70,000	98.50	19,70,000	98.50

3.4 Details of changes in shareholding of promoters

1 As at 31.12.2025

S. No.	Promoter's Name	No. of shares at the beginning	% of Total Shares	No. of shares at the end	% of Total Shares	% change during the period
1	Kamal Baghi	5,99,996	30.00	23,99,984	30.00	-
2	Saurabh Baghi	13,70,000	68.50	54,80,000	68.50	-
3	Vaishali Saini	30,000	1.50	1,20,000	1.50	-

2 As at 31.03.2025

S. No.	Promoter's Name	No. of shares at the beginning	% of Total Shares	No. of shares at the end	% of Total Shares	% change during the period
1	Kamal Baghi	6,00,000	30.00	5,99,996	30.00	-
2	Saurabh Baghi	13,70,000	68.50	13,70,000	68.50	-
3	Vaishali Saini	30,000	1.50	30,000	1.50	-

3 As at 31.03.2024

S. No.	Promoter's Name	No. of shares at the beginning	% of Total Shares	No. of shares at the end	% of Total Shares	% change during the period
1	Kamal Baghi	19,20,000	96.00	6,00,000	30.00	(66.00)
2	Saurabh Baghi	50,000	2.50	13,70,000	68.50	66.00
3	Vaishali Saini	30,000	1.50	30,000	1.50	-

4 As at 31.03.2023

S. No.	Promoter's Name	No. of shares at the beginning	% of Total Shares	No. of shares at the end	% of Total Shares	% change during the period
1	Kamal Baghi	-	-	19,20,000	96.00	100.00
2	Saurabh Baghi	70,000	70.00	50,000	2.50	(67.50)
3	Vaishali Saini	30,000	30.00	30,000	1.50	(28.50)

3.5 Terms / Rights attached to equity shares

- The Company presently has one class of equity shares having at par value of ₹10 each. Each holder of equity shares is entitled to one vote per share.
- The company has not declared dividend during any period.
- In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

3.6 The number of shares are presented in absolute figures.

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

4 RESERVES & SURPLUS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Securities Premium</u>				
(a)	Opening Balance	190.00	190.00	190.00	-
(b)	Add - Premium on Issue of Equity Shares	-	-	-	190.00
(c)	Less - Amount utilized toward issue of fully paid bonus shares	190.00	-	-	-
	Sub-Total	-	190.00	190.00	190.00
2	<u>Surplus / (Deficit) in the Statement of Profit and Loss</u>				
(a)	Balance as per last Balance Sheet	779.19	245.29	79.73	8.50
(b)	Add - Profit for the period	404.48	533.90	165.56	71.23
(c)	Less - Amount utilized toward issue of fully paid bonus shares	410.00	-	-	-
	Sub-Total	773.67	779.19	245.29	79.73
	Grand Total	773.67	969.19	435.29	269.73

5 LONG TERM BORROWINGS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Term Loans</u>				
(a)	<u>Secured Loans</u>				
(i)	From Banks	221.05	1,840.40	1,732.02	586.88
(ii)	From NBFCs / Financial Institutions	3,577.43	546.25	568.24	198.97
(b)	<u>Unsecured Loans</u>				
(i)	From Banks	-	22.31	-	96.00
(ii)	From NBFCs / Financial Institutions	-	46.91	59.56	116.59
	Sub-Total	3,798.48	2,455.87	2,359.82	998.44
	Less - Current Maturities of Long Term Borrowings	363.80	375.69	425.88	278.58
	Sub-Total	3,434.68	2,080.18	1,933.94	719.86
2	Loans From Directors (Unsecured)	591.66	610.00	297.01	653.69
3	Inter-Corporate Deposits (Unsecured)	372.25	200.00	222.22	-
	Grand Total	4,398.59	2,890.18	2,453.17	1,373.55

5.1 Secured Term Loans

S. No.	Particulars	Repayment Period (In Months)	Rate of Interest*	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>From Banks</u>						
1	ICICI Bank Limited	16 - 84	9.50%	127.63	1,057.03	911.48	-
2	Axis Bank Limited	60 - 180	9.15% - 9.50%	21.80	764.60	820.54	-
3	Punjab National Bank	84	13.20%	71.62	18.77	-	-
4	Indian Bank	1 - 109	10.90%	-	-	-	563.73
5	HDFC Bank Limited	60	7.85% - 9.15%	-	-	-	17.94
6	Bank of India	36	9.50% - 10.50%	-	-	-	1.97
7	Kotak Mahindra Bank Limited	13	10.55%	-	-	-	3.24

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	Repayment Period (In Months)	Rate of Interest*	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
	<u>From NBFCs / FIs</u>						
1	Siemens Financial Services Private Limited	30 - 60	10.50% - 11.50%	97.46	406.60	421.07	84.83
2	PKF Finance Limited	47 - 48	14.75% - 18%	98.37	139.65	147.17	114.13
3	Tata Capital Limited	120	10.50%	1,658.97	-	-	-
4	Axis Finance Limited	120	10.75%	680.02	-	-	-
5	Bajaj Finance Limited	60	10.69%	236.44	-	-	-
6	Poonawalla Fincorp Limited	84 - 180	10%	806.17	-	-	-

Notes

- ICICI Bank Limited has sanctioned various loans for purchase of medical equipments which are primarily secured against the equipments purchased out of the respective loans. The bank has also sanctioned working capital term loans which are primarily secured against the current assets. The loans are further secured against the Land & Building owned by Saurabh Baghi and the personal guarantee of the promoters / directors. A credit facility availed was subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025 and balance were subsequently taken over by Tata Capital Limited prior to the signing of the financial statements.
- Axis Bank Limited has sanctioned loan against property (LAP) which is secured against land & building owned by Shikha Baghi and is further secured against personal guarantee of the promoters / directors and Shikha Baghi. The LAP availed was subsequently taken over by Poonawala Fincorp Limited vide Sanctioned Letter dated August 20, 2025. The bank has also sanctioned vehicle loan which is secured against hypothecation of the asset purchased out of the loan. The vehicle loan is further secured against personal guarantee of the promoters / directors.
- Punjab National Bank has sanctioned equipment loan which are primarily secured against the equipments purchased out of the loan. The loan is further secured against the FDRs in the name of the company and is further secured against personal guarantee of the promoters / directors.
- Indian Bank had sanctioned various loans for purchase of Medical Equipments which were primarily secured against the equipments purchased out of the respective loans. The bank had also loan for civil works within the hospital which was primarily secured against the assets created out of loan. The loans were further secured against the Land & Building owned by Saurabh Baghi and the personal guarantee of the promoters / directors. The credit facilities availed were subsequently taken over by ICICI Bank Limited vide Sanction Letter dated September 27, 2023.
- HDFC Bank Limited had sanctioned vehicle loans which were secured against hypothecation of the asset purchased out of the loan. The bank had also sanctioned a loan against used unencumbered vehicle.
- Bank of India had sanctioned gold loan against pledge of gold bonds held in the name of promoters / directors.
- Kotak Mahindra Bank Limited had sanctioned vehicle loan which were secured against hypothecation of the asset purchased out of the loan.
- Siemens Financial Services Private Limited has sanctioned various loans for the purchase of medical equipments which are secured against the medical equipments purchased out of the loans. The loans are further secured against personal guarantee of the promoters / directors. The few credit facilities availed were subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025 and balance were taken over by Tata Capital Limited prior to the signing of the financial statements.
- PKF Finance Limited has sanctioned various loans against used & unencumbered medical equipments which are secured against such equipments. The company had also sanctioned business loans for the working capital requirements. The loans are further secured against personal guarantee of the promoters / directors / designated partners and their relatives. The few credit facilities availed were subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025.
- Tata Capital Limited has sanctioned term loan against immovable property, current assets & movable fixed assets of the company. The loan is further secured against personal guarantee of the promoters / directors. The facility was extended by way of a takeover of the company's existing equipment and working capital loans of ICICI Bank Limited and Siemens Financial Services Private Limited vide Sanction Letter dated November 28, 2025.
- Axis Finance Limited has sanctioned loan against property (LAP) which is secured against land & building and is further secured against personal guarantee of the promoters / directors.
- Bajaj Finance Limited has sanctioned loan for the purchase of medical equipments which are secured against the medical equipments purchased out of the loan. The loan is further secured against personal guarantee of the Saurabh Baghi and Vaishali Saini.
- Poonawala Fincorp Limited has sanctioned loan against property (LAP) which is secured against land & building owned by Shikha Baghi and is further secured against personal guarantee of the promoters / directors and Shikha Baghi.

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

5.2 Unsecured Term Loans

S. No.	Particulars	Repayment Period (In Months)	Rate of Interest*	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
	<u>From Banks</u>						
1	IDFC First Bank Limited	48 - 60	9.25% - 11.50%	-	22.31	-	35.39
2	Axis Bank Limited	60	10.50%	-	-	-	60.61
	<u>From NBFCs / FIs</u>						
1	Moneywise Financial Services Private Limited	36	17.50%	-	19.72	36.37	50.45
2	SMFG India Credit Co. Limited	37	12.50%	-	27.19	23.19	-
3	Wampum Finance Private Limited	30	10.50% - 11.00%	-	-	-	66.14

Notes

- IDFC First Bank has sanctioned business term loan for working capital requirements. The promoters / directors are acting as co-borrower for such loans. The credit facility availed was subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025.
 - Axis Bank had sanctioned business term loan for working capital requirements.
 - Moneywise Financial Services Private Limited has sanctioned business term loan for the working capital requirements. The promoters / directors are acting as co-borrower for such loans. The credit facility availed was subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025.
 - SMFG India Credit Co. Limited has sanctioned business term loans for the working capital requirements. The promoters / directors are acting as co-borrower for such loans. The credit facility availed was subsequently taken over by Axis Finance Limited vide Sanction Letter dated May 26, 2025.
 - Wampum Finance Private Limited had sanctioned business term loan for the working capital requirements.
- 5.3 The loan from directors and inter-corporate deposits are repayable on demand when there is surplus cash available with the company and also based on management's assessment of repayment. The same have been classified as Non-Current as per agreements and the applicable provisions under relevant laws.
- 5.4 There has been no continuing default in repayment of loan's installments and it's interest thereon.

* The interest rates are subject to revision from time to time.

6 DEFERRED TAX LIABILITIES / (ASSETS) (NET)

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Deferred Tax Liability</u>				
(a)	Opening Balance	144.50	80.36	45.09	(2.00)
(b)	<u>On Account of Depreciation</u>				
(i)	Recognised in Statement of Profit & Loss	37.95	64.14	35.27	47.09
	Closing Balance	182.45	144.50	80.36	45.09
2	<u>Deferred Tax Asset</u>				
(a)	Opening Balance	(13.67)	(7.93)	(3.02)	-
(b)	<u>On Account of Provision for Employee Benefit Expenses</u>				
(i)	Recognised in Statement of Profit & Loss	(2.19)	(5.74)	(4.91)	(3.02)
	Closing Balance	(15.86)	(13.67)	(7.93)	(3.02)
	Net Deferred Tax Liabilities / (Asset)	166.59	130.83	72.43	42.07

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

7 OTHER LONG TERM LIABILITIES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Security Payable	160.00	35.00	50.00	-
	Grand Total	160.00	35.00	50.00	-

8 LONG TERM PROVISIONS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Provision for Employee Benefits	56.86	49.04	28.43	10.82
	Grand Total	56.86	49.04	28.43	10.82

9 SHORT TERM BORROWINGS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Loans Repayable on Demand				
(a)	Working Capital Facilities				
(i)	From Banks (Secured)	28.39	922.07	699.52	445.51
2	Current Maturities of Long Term Borrowings (Secured & Unsecured)	363.80	375.69	425.88	278.58
	Grand Total	392.19	1,297.76	1,125.40	724.09

9.1 Notes

- Working Capital Limits are availed from ICICI Bank Limited by way of Cash Credit Limit. The said limit is secured against inventories, book debts and other current assets of the company. The limits are also secured against the Land & Building owned by Saurabh Baghi and the personal guarantee of the promoters / directors. The working capital limit is repayable on demand and carries interest rate of 9.50% per annum subject to revision from time to time. The credit facility availed was subsequently taken over by Tata Capital Limited prior to the signing of the financial statements.
- Working Capital Limits are availed from Punjab National Bank by way of Cash Credit Limit and Overdraft against Fixed Deposit. The cash credit limit is secured against inventories, book debts and other current assets. The Overdraft against Fixed Deposit is secured against fixed deposit of the promoter / director. The limits are also secured against the personal guarantee of the promoters / directors and designated partners. The working capital limits are repayable on demand and carries interest rate of 13.20% per annum and 7.40% per annum subject to revision from time to time.
- Working Capital Limits as at March 31, 2023 were availed from Indian Bank by way of Cash Credit Limit. The said limit was secured against inventories, book debts and other current assets of the company. The limit was also secured against the Land & Building owned by Saurabh Baghi and against the personal guarantee of the promoters / directors. The working capital limit was repayable on demand and carries interest rate of 10.90% per annum subject to revision from time to time. The credit facility availed was subsequently taken over by ICICI Bank Limited vide Sanction Letter dated September 27, 2023.

- 9.2 The Quarterly Returns or Statements of Current Assets filed with the Banks or FI's are in agreement with the books of accounts.

10 TRADE PAYABLES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Due to MSME (Unsecured)	93.91	59.99	23.55	57.57
2	Due to Other than MSME (Unsecured)	735.26	617.72	533.65	433.47
	Grand Total	829.17	677.71	557.20	491.04

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

10.1 Trade Payables Ageing Schedule

1 As at 31.12.2025

S. No.	Particulars	Outstanding for following periods from the due date				
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	Total
1	MSME	93.91	-	-	-	93.91
2	Others	677.30	51.88	1.28	4.80	735.26
3	Disputed Dues - MSME	-	-	-	-	-
4	Disputed Dues - Others	-	-	-	-	-
	Grand Total	771.21	51.88	1.28	4.80	829.17

2 As at 31.03.2025

S. No.	Particulars	Outstanding for following periods from the due date				
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	Total
1	MSME	59.99	-	-	-	59.99
2	Others	538.81	70.36	8.55	-	617.72
3	Disputed Dues - MSME	-	-	-	-	-
4	Disputed Dues - Others	-	-	-	-	-
	Grand Total	598.80	70.36	8.55	-	677.71

3 As at 31.03.2024

S. No.	Particulars	Outstanding for following periods from the due date				
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	Total
1	MSME	23.55	-	-	-	23.55
2	Others	508.23	9.14	16.28	-	533.65
3	Disputed Dues - MSME	-	-	-	-	-
4	Disputed Dues - Others	-	-	-	-	-
	Grand Total	531.78	9.14	16.28	-	557.20

4 As at 31.03.2023

S. No.	Particulars	Outstanding for following periods from the due date				
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	Total
1	MSME	57.57	-	-	-	57.57
2	Others	331.66	101.81	-	-	433.47
3	Disputed Dues - MSME	-	-	-	-	-
4	Disputed Dues - Others	-	-	-	-	-
	Grand Total	389.23	101.81	-	-	491.04

5 There are no Unbilled Trade Payables as at December 31, 2025, March 31, 2025, March 31, 2024 & March 31, 2023.

6 Dues to Micro and Small Enterprises as defined under the MSMED Act, 2006 have been determined to the extent such parties have been identified on the basis of information collected by the management.

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting period				
(a)	Principal amount due to micro and small enterprises	93.91	59.99	23.55	57.57
(b)	Interest due on above	-	-	-	-
	Total	93.91	59.99	23.55	57.57

ABH HEALTHCARE LIMITED*(Formerly known as ABH Healthcare Private Limited)***Notes forming part of the Restated Consolidated Financial Statements***(Amount in ₹ Lakhs, unless otherwise stated)*

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
2	The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting period.	-	-	-	-
3	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding the interest specified under the MSMED Act 2006.	-	-	-	-
4	The amount of interest accrued and remaining unpaid at the end of each accounting period.	-	-	-	-
5	The amount of further interest remaining due and payable even in the succeeding period, until such date when the interest due as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act 2006.	-	-	-	-

11 OTHER CURRENT LIABILITIES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Expenses Payable	52.56	49.66	110.85	51.99
2	Statutory Dues Payable	129.29	75.03	82.38	105.64
3	Security Payable	161.43	5.08	15.23	15.86
4	Interest Accrued but not due on Borrowings	9.61	9.99	4.11	1.14
5	Cheques Issued but not Presented	-	-	-	10.00
	Grand Total	352.89	139.76	212.57	184.63

12 SHORT TERM PROVISIONS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Provision for Employee Benefits	0.16	0.13	0.09	0.04
	Grand Total	0.16	0.13	0.09	0.04

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

13 Property, Plant & Equipment and Intangible Assets

13.1 The details of Property, Plant & Equipment (Net)

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Property, Plant & Equipment</u>				
(a)	Building	1,457.21	1,494.86	1,267.61	703.10
(b)	Medical Equipment	1,762.70	1,775.30	1,700.82	1,275.28
(c)	General Equipments	237.73	249.22	252.01	149.35
(d)	Vehicles	62.89	77.99	91.22	68.64
(e)	Furniture	47.35	52.13	51.79	51.61
(f)	Computer & Computer Peripherals	7.32	9.44	11.86	17.04
2	<u>Other Intangible Assets</u>				
(a)	Computer Software	2.61	3.96	5.76	7.56
3	<u>Capital Work in Progress</u>	53.00	-	-	62.76
	Grand Total	3,630.81	3,662.90	3,381.07	2,335.34

13.2 Property, Plant & Equipment

S. No.	Particulars	Building	Medical Equipment	General Equipments	Vehicles	Furniture	Computer & Computer Peripherals	Total
A	GROSS BLOCK							
1	As at 01.04.2022	727.09	1,306.57	154.82	78.35	53.65	25.06	2,345.54
2	Additions	-	104.94	5.75	-	3.49	0.31	114.49
3	Disposals / Adj.	-	34.90	-	-	-	-	34.90
4	As at 31.03.2023	727.09	1,376.61	160.57	78.35	57.14	25.37	2,425.13
5	Additions	587.59	732.65	115.03	33.08	5.77	2.98	1,477.10
6	Disposals / Adj.	-	218.97	-	-	-	-	218.97
7	As at 31.03.2024	1,314.68	1,890.29	275.60	111.43	62.91	28.35	3,683.26
8	Additions	268.88	194.61	15.34	-	6.59	7.05	492.47
9	Disposals / Adj.	-	-	0.23	-	-	-	0.23
10	As at 31.03.2025	1,583.56	2,084.90	290.71	111.43	69.50	35.40	4,175.50
11	Additions	-	89.92	2.35	-	0.18	0.43	92.88
12	Disposals / Adj.	-	-	-	9.42	-	-	9.42
13	As at 31.12.2025	1,583.56	2,174.82	293.06	102.01	69.68	35.83	4,258.96
B	ACCUMULATED DEPRECIATION							
1	As at 01.04.2022	0.97	3.96	1.21	0.41	0.22	0.34	7.11
2	Charge for the period	23.02	98.45	10.01	9.30	5.31	7.99	154.08
3	Disposals / Adj.	-	1.08	-	-	-	-	1.08
4	As at 31.03.2023	23.99	101.33	11.22	9.71	5.53	8.33	160.11
5	Charge for the period	23.08	112.75	12.37	10.50	5.59	8.16	172.45
6	Disposals / Adj.	-	24.61	-	-	-	-	24.61
7	As at 31.03.2024	47.07	189.47	23.59	20.21	11.12	16.49	307.95
8	Charge for the period	41.63	120.13	17.90	13.23	6.25	9.47	208.61
9	Disposals / Adj.	-	-	-	-	-	-	-
10	As at 31.03.2025	88.70	309.60	41.49	33.44	17.37	25.96	516.56
11	Charge for the period	37.65	102.52	13.84	9.74	4.96	2.55	171.26
12	Disposals / Adj.	-	-	-	4.06	-	-	4.06
13	As at 31.12.2025	126.35	412.12	55.33	39.12	22.33	28.51	683.76
C	NET BLOCK							
1	As at 31.12.2025	1,457.21	1,762.70	237.73	62.89	47.35	7.32	3,575.20
2	As at 31.03.2025	1,494.86	1,775.30	249.22	77.99	52.13	9.44	3,658.94
3	As at 31.03.2024	1,267.61	1,700.82	252.01	91.22	51.79	11.86	3,375.31
4	As at 31.03.2023	703.10	1,275.28	149.35	68.64	51.61	17.04	2,265.02

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

13.3 Other Intangible Assets

S. No.	Particulars	Computer Software
A	GROSS BLOCK	
1	As at 01.04.2022	9.44
2	Additions	-
3	Disposals / Adjustment	-
4	As at 31.03.2023	9.44
5	Additions	-
6	Disposals / Adjustment	-
7	As at 31.03.2024	9.44
8	Additions	-
9	Disposals / Adjustment	-
10	As at 31.03.2025	9.44
11	Additions	-
12	Disposals / Adjustment	-
13	As at 31.12.2025	9.44
B	ACCUMULATED DEPRECIATION	
1	As at 01.04.2022	0.08
2	Charge for the year	1.80
3	Disposals / Adjustments	-
4	As at 31.03.2023	1.88
5	Charge for the year	1.80
6	Disposals / Adjustments	-
7	As at 31.03.2024	3.68
8	Charge for the period	1.80
9	Disposals / Adjustments	-
10	As at 31.03.2025	5.48
11	Charge for the period	1.35
12	Disposals / Adjustments	-
13	As at 31.12.2025	6.83
C	NET BLOCK	
1	As at 31.12.2025	2.61
2	As at 31.03.2025	3.96
3	As at 31.03.2024	5.76
4	As at 31.03.2023	7.56

13.4 Capital Work in Progress Ageing Schedule

1 As at 31.12.2025

S. No.	Particulars	Amount in CWIP for a period of				Total
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	
1	Projects in progress	53.00	-	-	-	53.00
2	Projects temporarily suspended	-	-	-	-	-
	Grand Total	53.00	-	-	-	53.00

2 As at 31.03.2025

S. No.	Particulars	Amount in CWIP for a period of				Total
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	
1	Projects in progress	-	-	-	-	-
2	Projects temporarily suspended	-	-	-	-	-
	Grand Total	-	-	-	-	-

ABH HEALTHCARE LIMITED*(Formerly known as ABH Healthcare Private Limited)***Notes forming part of the Restated Consolidated Financial Statements***(Amount in ₹ Lakhs, unless otherwise stated)***3 As at 31.03.2024**

S. No.	Particulars	Amount in CWIP for a period of				Total
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	
1	Projects in progress	-	-	-	-	-
2	Projects temporarily suspended	-	-	-	-	-
	Grand Total	-	-	-	-	-

4 As at 31.03.2023

S. No.	Particulars	Amount in CWIP for a period of				Total
		Less than 1 year	1-2 years	2-3 Years	More than 3 years	
1	Projects in progress	62.76	-	-	-	62.76
2	Projects temporarily suspended	-	-	-	-	-
	Grand Total	62.76	-	-	-	62.76

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

14 GOODWILL

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Goodwill (Refer Note 41.1)	5.01	5.01	-	-
	Grand Total	5.01	5.01	-	-

15 NON CURRENT INVESTMENTS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Other Investments</u>				
(a)	Investment in Fixed Deposit of Banks*	179.94	28.61	12.07	-
	Grand Total	179.94	28.61	12.07	-

* Out of the total investments in Fixed Deposits as at 31.12.2025, ₹120 Lakhs, has been placed with scheduled bank as security against the credit facility availed from the bank.

16 NON CURRENT ASSETS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Security Deposits	11.26	32.36	29.61	20.77
	Grand Total	11.26	32.36	29.61	20.77

17 INVENTORIES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Medicines & Consumables (Valued at lower of Cost or Net Realisable Value)	307.31	445.78	289.10	225.90
	Grand Total	307.31	445.78	289.10	225.90

18 TRADE RECEIVABLES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Unsecured, Considered Good	3,324.73	1,973.61	1,197.87	589.27
	Grand Total	3,324.73	1,973.61	1,197.87	589.27

18.1 Trade Receivables Ageing Schedule

1 As at 31.12.2025

S. No.	Particulars	Outstanding for following periods from the due date					Total
		Less than 6 Months	6 Months - 1 Year	1-2 years	2-3 Years	More than 3 years	
1	<u>Undisputed Trade Receivables</u>						
(a)	Considered Good	2,010.91	562.37	724.07	27.38	-	3,324.73
(b)	Considered Doubtful	-	-	-	-	-	-
2	<u>Disputed Trade Receivables</u>						
(a)	Considered Good	-	-	-	-	-	-
(b)	Considered Doubtful	-	-	-	-	-	-
	Grand Total	2,010.91	562.37	724.07	27.38	-	3,324.73

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

2 As at 31.03.2025

S. No.	Particulars	Outstanding for following periods from the due date					Total
		Less than 6 Months	6 Months - 1 Year	1-2 years	2-3 Years	More than 3 years	
1	<u>Undisputed Trade Receivables</u>						
(a)	Considered Good	1,331.52	456.17	185.92	-	-	1,973.61
(b)	Considered Doubtful	-	-	-	-	-	-
2	<u>Disputed Trade Receivables</u>						
(a)	Considered Good	-	-	-	-	-	-
(b)	Considered Doubtful	-	-	-	-	-	-
	Grand Total	1,331.52	456.17	185.92	-	-	1,973.61

3 As at 31.03.2024

S. No.	Particulars	Outstanding for following periods from the due date					Total
		Less than 6 Months	6 Months - 1 Year	1-2 years	2-3 Years	More than 3 years	
1	<u>Undisputed Trade Receivables</u>						
(a)	Considered Good	1,077.18	8.12	112.57	-	-	1,197.87
(b)	Considered Doubtful	-	-	-	-	-	-
2	<u>Disputed Trade Receivables</u>						
(a)	Considered Good	-	-	-	-	-	-
(b)	Considered Doubtful	-	-	-	-	-	-
	Grand Total	1,077.18	8.12	112.57	-	-	1,197.87

4 As at 31.03.2023

S. No.	Particulars	Outstanding for following periods from the due date					Total
		Less than 6 Months	6 Months - 1 Year	1-2 years	2-3 Years	More than 3 years	
1	<u>Undisputed Trade Receivables</u>						
(a)	Considered Good	583.81	2.49	2.97	-	-	589.27
(b)	Considered Doubtful	-	-	-	-	-	-
2	<u>Disputed Trade Receivables</u>						
(a)	Considered Good	-	-	-	-	-	-
(b)	Considered Doubtful	-	-	-	-	-	-
	Grand Total	583.81	2.49	2.97	-	-	589.27

19 CASH AND CASH EQUIVALENTS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Cash in Hand	56.73	45.29	0.60	3.98
2	Balances with Banks	161.79	15.81	1.01	11.18
	Grand Total	218.52	61.10	1.61	15.16

20 SHORT TERM LOANS & ADVANCES

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Unsecured, Considered Good</u>				
	Advances to Suppliers	103.31	44.91	39.73	21.29
2	Advances to Contractors	-	-	-	-
	Grand Total	103.31	44.91	39.73	21.29

ABH HEALTHCARE LIMITED*(Formerly known as ABH Healthcare Private Limited)***Notes forming part of the Restated Consolidated Financial Statements***(Amount in ₹ Lakhs, unless otherwise stated)***21 OTHER CURRENT ASSETS**

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Balances with Revenue Authorities</u>				
(a)	TDS & Advance Tax	189.10	190.25	177.30	85.61
(b)	MAT Credit	-	21.00	48.24	21.03
(c)	<u>Less</u> - Provision for Tax	100.17	122.68	52.07	21.03
(d)	<u>Net Balance</u>	88.93	88.57	173.47	85.61
2	Other Assets	61.51	47.55	10.05	2.63
	Grand Total	150.44	136.12	183.52	88.24

21.1 Mat Credit Movement

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	<u>Mat Credit Entitlement</u>				
(a)	Opening Balance	21.00	48.24	21.03	-
(b)	<u>Add</u> - Credit for the year	-	-	27.21	21.03
(c)	<u>Less</u> - Credit utilised during the year	21.00	27.24	-	-
(d)	<u>Closing Balance</u>	-	21.00	48.24	21.03

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED*(Formerly known as ABH Healthcare Private Limited)***Notes forming part of the Restated Consolidated Financial Statements***(Amount in ₹ Lakhs, unless otherwise stated)***22 REVENUE FROM OPERATIONS**

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
	<u>Sale of Services</u>				
1	Revenue from In Patient Department Services	3,250.20	4,120.30	3,476.03	2,376.89
2	Revenue from Out Patient Department Services	387.61	550.71	462.45	474.13
	<u>Sub-Total</u>	3,637.81	4,671.01	3,938.48	2,851.02
3	<u>Other Operating Revenue from Outsourced Operations</u>				
(a)	Income from Pharmacy	210.44	222.80	174.46	93.90
(b)	Other Miscellaneous Operating Revenue	31.01	32.90	25.08	16.14
	Grand Total	3,879.26	4,926.71	4,138.02	2,961.06

23 OTHER INCOME

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Interest Income	3.26	4.28	0.86	-
2	Profit on Sale of PPE (net)	0.19	-	-	-
3	Miscellaneous Income	0.42	0.74	0.59	-
	Grand Total	3.87	5.02	1.45	-

24 COST OF MATERIALS CONSUMED

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Cost of Materials Consumed	813.05	1,024.20	1,132.19	809.02
	Grand Total	813.05	1,024.20	1,132.19	809.02

25 EMPLOYEE BENEFIT EXPENSES

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Director's Remuneration	17.00	46.01	12.00	-
2	Salaries	605.08	706.50	623.34	515.96
3	Contribution to Employee Benefit Funds	54.43	92.29	70.36	51.38
4	Staff Welfare Expenses	3.75	4.69	0.62	2.38
	Grand Total	680.26	849.49	706.32	569.72

ABH HEALTHCARE LIMITED*(Formerly known as ABH Healthcare Private Limited)***Notes forming part of the Restated Consolidated Financial Statements****26 FINANCE COST**

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Interest on Working Capital	60.07	69.17	60.10	30.71
2	Interest on Term Loans	185.70	243.97	158.60	88.80
3	Interest on Unsecured Loans from Director & Inter-Corporate Deposits	18.00	33.89	61.29	1.30
4	Bank Charges	52.95	24.07	15.71	12.18
	Grand Total	316.72	371.10	295.70	132.99

27 DEPRECIATION

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Depreciation	171.26	208.61	172.45	154.08
2	Amortisation	1.35	1.80	1.80	1.80
	Grand Total	172.61	210.41	174.25	155.88

28 OTHER EXPENSES

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
A	<u>Direct Expenses</u>				
1	Consumption of Misc. Consumables	30.70	53.15	50.48	44.47
2	Doctor's Professional Charges	888.82	1,162.17	1,004.27	736.43
3	Electricity Expenses	104.04	144.93	144.42	124.35
4	Outsourcing Charges	72.58	56.87	21.01	36.54
5	Other Misc. Direct Expenses	2.49	8.74	2.96	3.10
	Sub-Total	1,098.63	1,425.86	1,223.14	944.89
B	<u>Indirect Expenses</u>				
1	Advertisement	43.46	36.40	29.85	22.79
2	Annual Maintenance Charges	23.51	12.22	14.73	4.96
3	Audit Fees (Refer Note 28.1)	2.36	2.07	1.48	1.48
4	Director's Sitting Fees	2.80	2.10	-	-
5	Fees & Taxes	6.72	20.88	6.09	5.83
6	Insurance	3.23	2.11	6.73	5.59
7	Loss on sale of PPE	-	-	74.29	1.90
8	Pollution Control Expenses	6.36	12.96	7.70	4.75
9	Professional & Legal Expenses	43.84	51.84	39.20	34.90
10	Rebates, Discounts & Deductions	49.32	72.15	145.47	42.00
11	Rent Expenses	8.03	3.18	1.10	-
12	Repairs - Machinery	16.73	15.51	13.78	6.45
13	Repairs - Building	-	-	-	55.70
14	Repairs - Computer	5.47	8.88	10.15	11.56
15	Repairs - Others	8.72	18.61	13.84	16.54
16	Travelling & Other Transportation Expenses	11.89	29.78	10.79	8.11
17	Miscellaneous Expenses*	7.60	18.96	11.89	10.22
	Sub-Total	240.04	307.65	387.09	232.78
	Grand Total	1,338.67	1,733.51	1,610.23	1,177.67

* Miscellaneous Expenses do not include any expenses over and above ₹5 Lakhs

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

28.1 Detail of Audit Fees

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	For Statutory Audit	2.36	1.77	1.18	1.18
2	For Tax Audit	-	0.30	0.30	0.30
	Grand Total	2.36	2.07	1.48	1.48

28.2 Details of CSR Expenditure

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Gross Amount required to be spent by the Company during the year	7.82	-	-	-
2	<u>Amount spent during the year</u>				
(a)	Construction / Acquisition of any asset	-	-	-	-
(b)	On purposes other than (a) above	-	-	-	-
3	(Excess) / Shortfall at the end of the period	7.82	-	-	-
4	Total of previous year shortfall	-	-	-	-
5	Reason for shortfall	Period available upto March, 2026	-	-	-
6	Nature of CSR activities	-	-	-	-

This space below has been intentionally left blank

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

29 EARNING PER SHARE

- 29.1 The calculation of Earning Per Share (EPS) as disclosed in the statement of profit and loss has been made in accordance with Accounting Standard (AS) - 20 "Earning Per Share"
- 29.2 A Statement on calculation of Basic & Diluted EPS is as under -

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Calculation of Weighted Average No. of Shares				
(a)	Equity Shares at the beginning of the period	20,00,000	20,00,000	20,00,000	1,00,000
(b)	Equity Shares at the end of the period	80,00,000	20,00,000	20,00,000	20,00,000
(c)	Weighted Average No. of Shares*	80,00,000	80,00,000	80,00,000	67,66,301
2	Net Profit after Tax available for the equity shareholders	404.89	534.70	165.56	71.23
3	Basic Earning per Share	5.06	6.68	2.07	1.05
4	Diluted Earning per Share#	5.06	6.68	2.07	1.05
5	Face Value Of Equity Share	10.00	10.00	10.00	10.00

* Includes 60,00,000 bonus equity shares issued on April 29, 2025

There are no Potential Equity Shares

30 POST EMPLOYMENT BENEFITS

(a) Defined Benefit Obligation

The following tables summarise the components of net benefit expense recognised in the Statement of profit or loss and the funded status and amounts recognised in the balance sheet for the respective plans -

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
		Gratuity			
1	Cost for the year included under Employee Benefit				
(a)	Current Service Cost	10.38	21.85	16.23	10.85
(b)	Interest cost on Benefit Obligation	1.67	2.02	0.80	-
(c)	Prior Period Item	-	-	-	-
(d)	Actuarial Loss / (Gain)	(4.19)	(3.22)	0.63	-
2	Net Benefit Expense	7.86	20.65	17.66	10.85

(b) Benefit (Asset) / Liability -

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
		Gratuity			
1	Present value of Defined Benefit Obligation	57.02	49.16	28.51	10.85
2	Fair value of Plan Assets	-	-	-	-
	Net Asset / (Liability)	57.02	49.16	28.51	10.85

(c) Net (Assets) / Liabilities recognized in the Balance Sheet and experience adjustments on Actuarial Gain / (Loss) for Benefit Obligation and Plan Assets

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
		Gratuity			
1	Benefit Obligation as at the beginning of the year	49.16	28.51	10.85	-
2	Current Service Cost	10.38	21.85	16.23	10.85
3	Interest Cost	1.67	2.02	0.80	-
4	Prior Period Liability	-	-	-	-
5	Benefit Paid	-	-	-	-
6	Actuarial Loss / (Gain)	(4.19)	(3.22)	0.63	-
	Closing Defined Benefit Obligation	57.02	49.16	28.51	10.85

(d) There are no Plan Assets in the company.

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

(c) Mortality Table

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
Gratuity					
1	Discount Rate	7.00%	6.80%	7.10%	7.40%
2	Rate of Increase in Compensation Levels	5.00%	5.00%	5.00%	5.00%
3	Withdrawal Rates	5.00%	5.00%	5.00%	5.00%
4	Expected Average remaining Working Lives of Employees (Years)	33.18 Years	32.56 Years	32.92 Years	32.09 Years
5	Retirement Age (years)	65 Years	65 Years	65 Years	65 Years
6	Mortality Rate	IALM 2012-14 Ultimate	IALM 2012-14 Ultimate	IALM 2012-14 Ultimate	IALM 2012-14 Ultimate

The estimates of future salary increases, considered in actuarial valuation, takes account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(f) Amounts for the Current and Previous periods are as follows -

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
Gratuity					
1	Present Value of Obligation	57.02	49.16	28.51	10.85
2	Plan Assets	-	-	-	-
3	Surplus / (Deficit)	(57.02)	(49.16)	(28.51)	(10.85)
4	Experience adjustments on plan liabilities - (Loss) / Gain	2.73	5.16	0.49	-
5	Experience adjustments on plan assets - (Loss) / Gain	-	-	-	-

31 LEASES

General Description of the Company's Operating Lease Arrangements -

31.1 The Company has entered into lease arrangement dated November 26, 2024 for the Hospital Building, the significant terms and conditions are as follows -

- The tenure of the lease agreement is for a period of 61 months.
- The lease payments are subject to 10% increment every year.

31.2 The minimum lease payments to be made in future towards non-cancellable lease agreements are as follows -

Estimated future minimum payments

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Not later than one year	1.34	1.25	-	-
2	Later than one year and not later than five years	4.73	5.74	-	-
3	Later than five years	-	-	-	-

32 SEGMENT INFORMATION

As per requirement of AS-17, "Segment Reporting", no disclosures are required to be made since the company's activities consists of a single business segment under single geographical location.

33 RELATED PARTY INFORMATION

As per AS - 18, the disclosure of the related parties and transactions with them are given below -

33.1 List of Related Parties are as follows -

S. No.	Name of the Related Party	Nature of Relationship
1	Kamal Baghi	Chairman
2	Saurabh Baghi	Managing Director
3	Vaishali Saini	Wholtime Director
4	Shikha Baghi	Relative of KMP
5	Satnam Singh Nijjar	Independent Director
6	Yog Raj Saini	Independent Director
7	Balwinder Singh	Independent Director
8	Anil Kumar Rangra	Chief Financial Officer (Resigned w.e.f 28.02.2025)
9	Rajeev Agarwal	Chief Financial Officer
10	Rahul Sharma	Company Secretary

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Name of the Related Party	Nature of Relationship
11	Five Creeks Healthcare LLP*	Enterprises over which company has Control
12	ABH Clinics LLP*	
13	Anil Baghi Hospital (Proprietor Kamal Baghi)	Enterprise over which KMP or their relatives can exercise Significant Influence
14	Kamal & Richa IVF LLP	
15	Kamal Baghi HUF	
16	Satya Pal Baghi Charitable Society	
17	Timeless Aesthetics Metros LLP	
18	Timeless Promise Foundation	
19	Beyond Smiles	

* ABH Healthcare Limited has acquired 90% share w.e.f. November 20, 2024.

33.2 Related Party Transactions are as follows -

S. No.	Particulars of Transactions*	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Key Managerial Personnel				
(i)	Remuneration				
(a)	Kamal Baghi	17.00	46.01	12.00	-
(b)	Anil Kumar Rangra	-	1.50	-	-
(c)	Rajeev Agarwal	17.10	1.90	-	-
(d)	Rahul Sharma	3.60	3.20	-	-
(ii)	Professional Fees				
(a)	Kamal Baghi	103.50	108.00	-	-
(b)	Saurabh Baghi	90.00	120.00	121.00	80.00
(c)	Vaishali Saini	90.00	120.00	120.00	80.00
(iii)	Sitting Fees				
(a)	Vaishali Saini	1.50	1.40	-	-
(b)	Yog Raj Saini	0.60	0.50	-	-
(c)	Satnam Singh Nijjar	0.50	0.20	-	-
(d)	Balwinder Singh	0.20	-	-	-
(iv)	Rent Paid				
(a)	Saurabh Baghi	0.92	0.42	-	-
(v)	Issue of Shares including Securities Premium				
(a)	Kamal Baghi	-	-	-	380.00
(vi)	Unsecured Loan Raised				
(a)	Kamal Baghi	26.22	9.30	119.85	-
(b)	Saurabh Baghi	63.88	374.35	80.30	74.50
(c)	Vaishali Saini	19.00	164.85	176.00	48.00
(vii)	Unsecured Loan Repaid				
(a)	Kamal Baghi	35.08	129.15	-	-
(b)	Saurabh Baghi	56.35	100.23	63.80	51.81
(c)	Vaishali Saini	36.01	33.10	83.15	2.88
(viii)	Interest on Unsecured Loan				
(a)	Kamal Baghi	-	8.90	40.82	-
2	Closing Balances				
(i)	Key Managerial Personnel				
(a)	Kamal Baghi (Cr.) (Unsecured Loan)	0.64	9.49	119.85	585.87
(b)	Kamal Baghi (Cr.) (Director Remuneration)	1.67	-	9.60	-
(c)	Kamal Baghi (Cr.) (Professional Fees)	-	9.00	-	-
(d)	Saurabh Baghi (Cr.) (Unsecured Loan)	330.84	320.78	39.19	22.69
(e)	Saurabh Baghi (Cr.) (Professional Fees)	0.21	7.97	7.21	-
(f)	Saurabh Baghi (Cr.) (Rent Payable)	1.34	0.42	-	-

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars of Transactions*	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
(g)	Vaishali Saini (Cr.) (Unsecured Loan)	260.18	279.72	137.97	45.13
(h)	Vaishali Saini (Cr.) (Professional Fees)	4.97	0.70	9.32	-
(i)	Vaishali Saini (Cr.) (Sitting Fees)	0.30	0.70	-	-
(j)	Rajeev Aggarwal (Cr.) (Remuneration)	1.90	1.90	-	-
(k)	Rahul Sharma (Cr.) (Remuneration)	0.40	0.40	-	-
(l)	Yograj Saini (Cr.) (Sitting Fees)	1.10	0.50	-	-
(m)	Satnam Singh Nijjar (Cr.) (Sitting Fees)	0.70	0.20	-	-
(n)	Balwinder Singh Chhina (Cr.) (Sitting Fees)	0.20	-	-	-

* The company has taken over the ongoing business of Anil Baghi Hospital (Proprietorship Concern of Kamal Baghi, Promoter of the Company) w.e.f. March 16, 2022. Therefore, wrong pocket adjustments are ignored while preparing the Related Party Transactions in lieu of the agreed clauses mentioned in the Business Transfer Agreement.

34 EARNINGS & EXPENDITURE IN FOREIGN CURRENCY

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Earnings in Foreign Currency	-	-	-	-
2	Expenditure in Foreign Currency	-	-	-	-

35 CONTINGENT LIABILITIES & COMMITMENTS

- 35.1 There are outstanding demands of ₹6.24 Lakhs related to TDS defaults appearing on the TRACES portal as on date of preparation of the Restated Financial Statements. The defaults mainly relates to the short payment and short deduction of TDS, interest under section 201 and late filing fees under section 234E of Income Tax Act, 1961. The Income Tax Authorities has issued communication notices in this regard and the Authorities may at any time issue recovery notices in which event the same shall become payable.

36 EVENTS OCCURRING AFTER BALANCE SHEET DATE

- 36.1 There are no other material events which are occurring after the Balance Sheet Date and are required to be disclosed except for the events already disclosed under the respective heads.

37 IMPAIRMENT OF ASSETS

In accordance with AS-28 on "Impairment of Assets" the Company has assessed as on the balance sheet date, whether there are any indications with regard to the impairment of any of the assets. Based on such assessment, it has been ascertained that no potential loss is present and therefore, formal estimate of recoverable amount has not been made. Accordingly, no impairment loss has been provided in the books of accounts.

38 RATIOS AND THEIR ANALYSIS

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023	% Change from March 31, 2024 to March 31, 2025	% Change from March 31, 2023 to March 31, 2024
1	<u>Current Ratio (times)</u>						
(a)	Current Assets	4,104.31	2,661.52	1,711.83	939.86		
(b)	Current Liabilities	1,574.41	2,115.36	1,895.26	1,399.80		
(c)		2.61	1.26	0.90	0.67	40.00%	34.33%
	(Current Assets / Current Liabilities)						
2	<u>Debt - Equity Ratio (Times)</u>						
(a)	Total Debt	4,800.39	4,197.93	3,582.68	2,098.78		
(b)	Total Equity	1,573.67	1,169.19	635.29	469.73		
(c)	(Debt / Equity)	3.05	3.59	5.64	4.47	36.35%	26.17%

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023	% Change from March 31, 2024 to March 31, 2025	% Change from March 31, 2023 to March 31, 2024
3	<u>Debt Service Coverage Ratio (Times)</u>						
(a)	EBITDA - Taxes	841.27	1,092.14	619.80	347.92		
(b)	Debt Service during the period	533.70	796.31	406.19	331.15		
(c)	<i>((EBITDA - Taxes) / Debt Service during the Period)</i>	1.58	1.37	1.53	1.05	-10.12%	45.23%
4	<u>Return on Equity Ratio (%)</u>						
(a)	Profit After Tax	404.89	534.70	165.56	71.23		
(b)	Average Shareholder's Equity	1,371.43	902.24	552.51	244.12		
(c)	<i>(Profit After Tax / Shareholder's Equity)</i>	30.00%	59.00%	30.00%	29.00%	96.67%	3.45%
5	<u>Inventory Turnover Ratio (Times)</u>						
(a)	Revenue from Operations	3,879.26	4,926.71	4,138.02	2,961.06		
(b)	Average Inventories	376.55	367.44	257.50	213.40		
(c)	<i>(Revenue from Operations / Average Inventories)</i>	10.30	13.41	16.07	13.88	-16.55%	15.78%
6	<u>Trade Receivables Turnover Ratio (Times)</u>						
(a)	Revenue from Operations	3,879.26	4,926.71	4,138.02	2,961.06		
(b)	Average Trade Receivables	2,649.17	1,585.74	893.57	306.09		
(c)	<i>(Revenue from Operations / Average Trade Receivables)</i>	1.46	3.11	4.63	9.67	-32.83%	-52.12%
7	<u>Trade Payables Turnover Ratio (Times)</u>						
(a)	Net Purchases	728.78	1,120.54	1,195.39	834.02		
(b)	Average Trade Payables	753.44	617.46	524.12	446.89		
(c)	<i>(Net Purchases / Average Trade Payables)</i>	0.97	1.81	2.28	1.87	-20.61%	21.93%
8	<u>Net Capital Turnover Ratio (Times)</u>						
(a)	Revenue from Operations	3,879.26	4,926.71	4,138.02	2,961.06		
(b)	Average Working Capital	1,538.03	181.37	-321.69	-691.69		
(c)	<i>(Revenue from Operations / Average Working Capital)</i>	2.52	27.16	N.A.^	N.A.^	N.A.	N.A.
9	<u>Return on Capital Employed (%)</u>						
(a)	EBIT	825.59	1,090.05	500.77	236.59		
(b)	Capital Employed	6,540.65	5,497.95	4,290.40	2,610.58		
(c)	<i>(EBIT / Capital Employed)</i>	13.00%	20.00%	12.00%	9.00%	66.67%	33.33%
10	<u>Net Profit Ratio (%)</u>						
(a)	Profit After Tax	404.89	534.70	165.56	71.23		
(b)	Revenue from Operations	3,879.26	4,926.71	4,138.02	2,961.06		
(c)	<i>(Profit After Tax / Revenue from Operations)</i>	10.00%	11.00%	4.00%	2.00%	175.00%	100.00%
11	<u>Return on Investment (%)</u>						
(a)	Return	3.26	0.90	0.07	-		
(b)	Amount of Investment	179.94	28.61	12.07	0.00		
(c)	<i>(Return / Amount of Investment)#</i>	7.00%	7.00%	7.00%	N.A.	0.00%	100.00%

* Ratios variances have been explained for any change by more than 25% as compared to the previous year.

** The company has not explained the reasons for variances in the ratios computed for the period ended December 31, 2025 in comparison with March 31, 2025 on account of non-comparability of reporting period.

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

^ Net Capital Turnover Ratio as at 31.03.2024 & 31.03.2023 is not computed because of negative working capital.

The return on investment (%) has been annualised.

38.1 Notes to Analytical Ratios

(a) % Change from March 31, 2024 to March 31, 2025

- 1 The variance in Current Ratio is on account of major increase in current assets of the company as compared to the previous year.
- 2 The variance in Debt-Equity Ratio is majorly on account of increased profitability in the current financial year as compared to the previous financial year.
- 3 The variance in Return on Equity Ratio is majorly on account of increased profitability of the company during the year as compared to the previous financial year.
- 4 The variance in Trade Receivables Turnover Ratio is on account of increase of average trade receivables on account of its slow recovery as compared to increased revenues during the period.
- 5 The variance in Return on Capital Employed is on account of increased EBIT as well capital employed of the company as compared to the previous financial year.
- 6 The variance in Net Profit Ratio is majorly on account of increased profitability in the current year as compared to the previous year.

(b) % Change from March 31, 2023 to March 31, 2024

- 1 The variance in Current Ratio is on account of major increase in current assets of the company as compared to the previous year.
- 2 The variance in Debt-Equity Ratio is on account of increased term loans and inter corporate deposits in the current financial year as compared to the previous financial year.
- 3 The variance in Debt Service Coverage Ratio is on account of increased operating profitability of the company as compared to the previous year, whereas there is gradual increase in the debt service during the year.
- 4 The variance in Trade Receivables Turnover Ratio is on account of sharp increase of average trade receivables on account of its slow recovery as compared to increased revenues during the period.
- 5 The variance in Return on Capital Employed is on account of increased EBIT as well capital employed of the company as compared to the previous financial year.
- 6 The variance in Net Profit Ratio is on account of increased PAT and revenue from operations in the current year as compared to the previous year.
- 7 The variance in Return on Investment is on account of the investments being made by the company in the F.Y. 2023-24 as compared to nil investments in the F.Y. 2022-23.

39 OTHER STATUTORY INFORMATION

- 1 There are no freehold immovable properties (Land) purchased by the company in current and previous financial years.
- 2 The Company has not revalued its property, plant and equipment during the current and previous year.
- 3 The company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- 4 The Company has not been declared wilful defaulter by any bank and financial institution or government or any government authority.
- 5 The Company do not have any transaction with companies struck off.
- 6 The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- 7 The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- 8 The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- 9 The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- 10 The Company have not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- 11 The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

40 OTHER INFORMATION

- 1 GST Inputs and Outputs are considered in the books of accounts w.r.t. the purchases / inputs and sales / outputs made during the year on which the assessee is eligible / liable by the management. However, difference if any, resulting at the time of GST Audit or any other development or information later on, is provided for in the year in which such difference is recognised.
- 2 In the opinion of the Directors, Trade Receivables and Other Current Assets have been valued at which they are shown in the Balance Sheet if realised in the ordinary course of business.
- 3 Balances of parties under Other Current Liabilities, Trade Receivables and Other Current Assets are subject to confirmation.
- 4 Previous Year Figures have been regrouped and recasted wherever necessary.
- 5 The figures reported in ₹ Lakhs have been rounded off to the nearest decimal in accordance with matching concept.

41 GROUP INFORMATION

- 41.1 The Company had acquired 90% share of 2 LLP's i.e. Five Creeks Healthcare LLP and ABH Clinics LLP w.e.f. November 20, 2024. Net Assets and Goodwill at the time of acquisition is calculated as follows -

S. No.	Particulars	ABH Clinics LLP	Five Creeks Healthcare LLP
		As at 19.11.2024	
1	Current Assets	1.29	70.99
2	Non Current Assets	2.23	45.73
3	Current Liabilities	4.69	8.12
4	Non Current Liabilities	-	109.74
5	Net Assets i.e. Total Assets minus Total Liabilities	(1.17)	(1.14)
6	Share in Net Assets attributable to ABH Healthcare Limited i.e. 90%	(1.05)	(1.03)
7	Share of Net Assets of Minority Interests borne by ABH Healthcare Limited i.e. 10%*	(0.12)	(0.11)
8	Total Net Assets attributable to ABH Healthcare Limited	(1.17)	(1.14)
9	Amount of Investment by ABH Healthcare Limited	0.90	1.80
10	Goodwill*	2.07	2.94

* At the time of acquisition of share in LLP's by the parent company, the accumulated losses exceed the amount of invested capital. Therefore, as per the applicable provisions, the share of loss of minority interest beyond their invested amount has been borne by the parent company, resulting into increased amount of goodwill.

- 41.2 The Profit Sharing Ratio is as follows:

S. No.	Particulars	Profit Sharing Ratio (%)			
		As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Five Creeks Healthcare LLP (Incorporated on 31.03.2023) :				
	- ABH Healthcare Limited	90.00	90.00	-	-
	- Minority Interests	10.00	10.00	100.00	100.00
2	ABH Clinics LLP (Incorporated on 05.06.2024) :				
	- ABH Healthcare Limited	90.00	90.00	-	-
	- Minority Interests	10.00	10.00	-	-

- 41.3 Summarised Balance Sheet as at 31.12.2025 & 31.03.2025

S. No.	Particulars	ABH Clinics LLP	Five Creeks Healthcare LLP	ABH Clinics LLP	Five Creeks Healthcare LLP
		As at 31.12.2025		As at 31.03.2025	
1	Current Assets	11.03	68.56	5.04	48.05
2	Non Current Assets	3.94	96.64	4.12	79.92
3	Current Liabilities	5.43	97.16	7.13	53.14
4	Non Current Liabilities	5.71	62.10	-	71.16
5	Net Assets i.e. Total Assets minus Total Liabilities	3.83	5.94	2.03	3.67
6	Percentage of Holding	90.00%	90.00%	90.00%	90.00%
7	Share of ABH Healthcare Limited in Net Assets	3.45	5.35	1.83	3.30

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

41.4 Summarised Profit & Loss for the period ended 31.12.2025 & 31.03.2025*

S. No.	Particulars	ABH Clinics LLP	Five Creeks Healthcare LLP	ABH Clinics LLP	Five Creeks Healthcare LLP
		For the period ended 31.12.2025		For the period ended 31.03.2025	
1	Total Revenue	6.18	68.80	6.16	30.34
2	Total Expenses	3.60	65.57	2.97	25.52
3	Profit before Tax	2.58	3.23	3.19	4.82
4	Tax Expense	0.77	0.97	-	-
5	Profit after Tax	1.81	2.26	3.19	4.82
6	Percentage of Holding	90.00%	90.00%	90.00%	90.00%
7	Share of ABH Healthcare Limited in Profit for the period	1.63	2.03	2.87	4.34

* Results for the period from 20.11.2024 to 31.03.2025 has been considered at the time consolidation for the period ended 31.03.2025.

41.5 Additional Information

S. No.	Name of the Entity	Net Assets i.e. Total Assets minus Total Liabilities		Share in Profit or Loss	
		As % of Consolidated Net Assets	Amount	As % of Consolidated Net Assets	Amount
1	Holding Company ABH Healthcare Limited As at 31.12.2025 As at 31.03.2025	99.23% 99.31%	1,562.78 1,161.97	99.00% 98.50%	400.82 526.69
1	Controlled Entities ABH Clinics LLP As at 31.12.2025 As at 31.03.2025	0.22% 0.16%	3.45 1.83	0.40% 0.54%	1.63 2.87
2	Five Creeks Healthcare LLP As at 31.12.2025 As at 31.03.2025	0.34% 0.28%	5.35 3.30	0.50% 0.81%	2.03 4.34
	Minority Interests in all Controlled Entities As at 31.12.2025 As at 31.03.2025	0.06% 0.05%	0.98 0.56	0.10% 0.15%	0.41 0.80
	Inter-Company Elimination and Consolidation Adjustments As at 31.12.2025 As at 31.03.2025	0.15% 0.20%	2.33 2.33	- -	- -
	Total As at 31.12.2025 As at 31.03.2025	100.00% 100.00%	1,574.88 1,169.99	100.00% 100.00%	404.89 534.70

42 SUMMARY OF RESTATEMENT ADJUSTMENTS

Statement of Restatement Adjustments to Audited Financial Statements is as follows -

42.1 Reconciliation between Audited Equity and Restated Equity

S. No.	Particulars	As at 31.12.2025	As at 31.03.2025	As at 31.03.2024	As at 31.03.2023
1	Equity as per Audited Financial Statements	1,573.67	1,169.19	660.59	482.03
(a)	Differences carried over pertaining to change in profit / loss due to restated effect for the previous period covered in Restated Financial	-	-	(12.30)	(7.99)
(b)	Differences pertaining to changes in profit / loss due to restated effect for the period covered in Restated Financial	-	-	(59.58)	(4.31)
(c)	Other Adjustments reclassified from Opening Reserves	-	-	46.58	-
2	Equity as per Restated Financial Statements	1,573.67	1,169.19	635.29	469.73

ABH HEALTHCARE LIMITED

(Formerly known as ABH Healthcare Private Limited)

Notes forming part of the Restated Consolidated Financial Statements

(Amount in ₹ Lakhs, unless otherwise stated)

42.2 Reconciliation between Audited Profit after Tax with Restated Profit after Tax

S. No.	Particulars	For the period ended 31.12.2025	For the period ended 31.03.2025	For the period ended 31.03.2024	For the period ended 31.03.2023
1	Profit after Tax as per Audited Financial Statements	404.89	534.70	225.14	75.53
(a)	Other Income	-	-	0.86	-
(b)	Employee Benefit Expenses	-	-	(17.66)	(10.85)
(c)	Finance Cost	-	-	(2.97)	0.78
(d)	Depreciation and Amortisation Expenses	-	-	4.39	2.77
(e)	Other Expenses	-	-	(75.76)	(3.37)
(f)	Deferred Tax Adjustment	-	-	31.56	6.37
2	Profit after Tax as per Restated Financial Statements	404.89	534.70	165.56	71.23

42.3 The Restated Financial Information includes certain restatements, reclassifications and adjustments to the Profit After Tax (PAT), Balance Sheet and other relevant financial figures, resulting in differences from the Statutory Financial Statements for the year ending March 31, 2024 which were approved by Board of Directors on September 16, 2024.

This space below has been intentionally left blank

CAPITALISATION STATEMENT

The following table sets forth our Company's capitalisation as at December 31, 2025, as derived from our Restated Consolidated Financial Information. This table should be read in conjunction with “*Risk Factors*”, “*Restated Consolidated Financial Statement*” and “*Management's Discussion and Analysis of Financial Condition and Results of Operations*” on pages 33,182 and 219, respectively –

(₹ in Lakhs)		
Particulars	Pre-Issue as at December 31, 2025	As adjusted for Issue ^{^*}
Borrowings		
Current borrowings*	28.39	-
Non-current borrowings (including current maturity)*	4,762.39	-
Interest Accrued but not due	9.61	-
Total borrowings (A)	4,800.39	-
Equity		
Equity share capital	800.00	-
Reserves & Surplus	773.67	-
Total Equity (B)	1,573.67	-
Non-current borrowings including current maturity of long-term debt /equity ratio (times)	3.03	-
Total borrowings/ equity ratio (A / B) (times)	3.05	-

[^]To be updated upon finalization of the Issue Price.

*the corresponding post-Issue figures will be calculated on conclusion of the Book Building process.

- 1) The above has been computed on the basis on amounts derived from Restated Financial Information as at December 31, 2025 on standalone basis.
- 2) The Company is proposing to have public Issue of Equity Shares.
- 3) The corresponding post-Issue capitalisation data for each of the above amounts given in the table is not determinable at this stage pending the completion of book building process and hence, the same have not been provided in the above statement.

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY CHAIRMAN & WHOLE-TIME DIRECTOR

Sd/-

DR. KAMAL BAGHI

DIN: 08449735

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY MANAGING DIRECTOR

Sd/-

DR. SAURABH BAGHI
DIN: 09088201

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY NON-EXECUTIVE DIRECTOR

Sd/-

DR. VAISHALI SAINI
DIN: 09088202

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY NON-EXECUTIVE INDEPENDENT DIRECTOR

Sd/-

MR. BALWINDER SINGH
DIN: 10920013

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY NON-EXECUTIVE INDEPENDENT DIRECTOR

Sd/-

DR. SATNAM SINGH NIJJAR
DIN: 01343663

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY COMPANY SECRETARY AND COMPLIANCE OFFICER

Sd/-

MR. RAHUL SHARMA

DECLARATION

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statements, disclosures and undertakings made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made, or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements, disclosures and undertakings in this Addendum are true and correct.

SIGNED BY CHIEF FINANCIAL OFFICER

Sd/-

MR. RAJEEV AGARWAL